Document:

Second Amended and Restated Registration Rights Agreement

 Exhibit 10.14 
 SECOND AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT 
 THIS SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is entered into as of March 25, 2003, by and
among CompHealth Group, Inc., a Delaware corporation formerly known as CMS Capital Ventures, Inc. (the “Company”), HEALTHSOUTH Corporation, a Delaware corporation (“HEALTHSOUTH”), each of the investors from time to
time listed on the Schedule of Investors attached here to (collectively, the “Investors” and each individually, an “Investor”), each of the warrantholders from time to time listed on the Schedule of
Warrantholders (collectively, the “Warrantholders” and each individually a “Warrantholder”) and each of the other Persons listed from time to time on the Schedule of Other Stockholders attached hereto
(collectively, the “Other Stockholders” and each individually, an “Other Stockholder”). 
 Certain of the
Investors and HEALTHSOUTH (collectively, the “Prior Investors”) hold shares of the Company’s common stock, par value $.01 per share (the “Common Stock”), and shares of the Company’s preferred stock, par
value $.01 per share (the “Preferred Stock”). 
 Certain of the Investors are purchasing shares of the Common Stock and
Preferred Stock (i) from HEALTHSOUTH pursuant to that certain Stock Purchase Agreement dated as of March 25, 2003, (ii) from Nassau Capital Partners II L.P. and NAS Partners I L.L.C. pursuant to that certain Stock Purchase Agreement
dated as of March 25, 2003 or (iii) from the Company pursuant to that certain Stock Purchase Agreement dated as of March 25, 2003 (collectively, the “Purchase Agreements”), and the obligations in the Purchase
Agreements are conditioned upon the execution and delivery of this Agreement. 
 The Company, the Prior Investors, the Warrantholders and the
Other Stockholders (collectively, the “Prior Stockholders”) are parties to an Amended and Restated Registration Rights Agreement made as of December 31, 1998 and amended and restated as of March 23, 2000 (the
“Prior Agreement”). The parties to the Prior Agreement desire to amend and restate the Prior Agreement and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties to this Agreement, intending to be legally bound, hereby agree as follows: 
 1. Demand
Registrations. 
 (a) Requests for Registration. At any time after the Company has completed an initial Public Offering of any of
its equity securities under the Securities Act (an “IPO”), the holders of a majority of the Investor Registrable Securities may request registration under the Securities Act of (x) all or any portion of their Registrable Securities on
Form S-l or any similar long-form registration (“Long-Form Registrations”), and (y) all or any portion of their Registrable Securities on Form S-2 or S-3 (including pursuant to Rule 415 under the Securities Act) or any similar
short-form registration (“Short-Form Registrations”) if available. All registrations 

  

 1. 

 
requested pursuant to this Section 1(a) are referred to herein as “Demand Registrations.” Each request for a Demand Registration shall
specify the approximate number of Registrable Securities requested to be registered and the anticipated per share price range for such offering. Within ten (10) days after receipt of any such request, the Company shall give written notice of
such requested registration to all other holders of Registrable Securities and, subject to Section l(d) below, shall include in such registration all Registrable Securities with respect to which the Company has received written requests for
inclusion therein within 15 days after the receipt of the Company’s notice (it being understood that no Warrants or other securities convertible into, or exercisable for, Registrable Securities shall be included in any such registration unless
such Warrants or other securities are, or will be in connection with such offering, converted or exercised prior to such registration). 
 (b) Long-Form Registrations. The holders of a majority of the Investor Registrable Securities shall be entitled to request (i) four (4) Long-Form Registrations in which the Company shall pay all registration expenses
(“Company-Paid Long-Form Registrations”) and (ii) an unlimited number of long-form registrations in which the holders of Registrable Securities shall pay their share of the Registration Expenses as set forth in Section 5
hereof. A registration shall not count as one of the permitted Long-Form Registrations until it has become effective and no Company-Paid Long-Form Registration shall count as one of the permitted Company-Paid Long-Form Registrations unless the
holders of Registrable Securities initially requesting the Long-Form Registration are able to register and sell at least 90% of the Registrable Securities requested to be included in such registration by such holders; provided that, in any
event, the Company shall pay all Registration Expenses in connection with any registration initiated as a Company-Paid Long-Form Registration whether or not it has become effective and whether or not such registration has counted as one of the
permitted Company-Paid Long-Form Registrations. All Long-Form Registrations shall be underwritten registrations. 
 (c) Short-Form
Registrations. In addition to the Long-Form Registrations provided pursuant to Section l(b), the holders of a majority of the Investor Registrable Securities shall be entitled to request an unlimited number of Short-Form Registrations in which
the Company shall pay all Registration Expenses. Demand Registrations shall be Short-Form Registrations whenever the Company is permitted to use any applicable short form. After the Company has become subject to the reporting requirements of the
Securities Exchange Act, the Company shall use its reasonable efforts to make Short-Form Registrations on Form S-3 available for the sale of Registrable Securities. 
 (d) Priority on Demand Registrations. The company shall not include in any Demand Registration any securities which are not Registrable Securities without the prior written consent of the holders of 66 2/3% of
the Investor Registrable Securities included in such registration, which consent shall not be unreasonably withheld. If a Demand Registration is an underwritten offering and the managing underwriters advise the company in writing that in their
opinion the number of Registrable Securities and, if permitted hereunder, other securities requested to be included in such offering exceeds the number of Registrable Securities and other securities, if any, which can be sold in an orderly manner in
such offering within a price range acceptable to the holders of a majority of the Investor Registrable Securities to be included in such registration therein, without adversely affecting the marketability of the offering, the Company shall include
in such registration prior to the inclusion of any securities which are not Registrable Securities 

  

 2. 

 
the number of Registrable Securities requested to be included which in the opinion of such underwriters can be sold in an orderly manner within the price
range offering without adversely affecting the marketability of the offering, first, pro rata among the respective holders of the Registrable Securities on the basis of the amount of Registrable Securities owned by each such holder and then, to the
extent that any securities which are not Registrable Securities can still be included pro rata among the respective holders thereof on the basis of the amount of such securities owned by each such holder. Any Persons other than holders of
Registrable Securities who participate in Demand Registrations which are not at the Company’s expense must pay their share of the Registration Expenses as provided in Section 5 hereof. 
 (e) Restrictions on Demand Registrations. The Company shall not be obligated to effect any Demand Registration prior to an IPO by the Company or
within 180 days after the effective date of a previous Demand Registration or a previous registration in which the holders of Registrable Securities were given piggyback rights pursuant to Section 2 and in which there was no reduction from the
number of Registrable Securities requested to be included. The Company may postpone for a reasonable period of time not to exceed 90 days the filing or the effectiveness of a registration statement for a Demand Registration if the Board determines
(in its reasonable business judgment) that such Demand Registration would reasonably be expected to have a material adverse effect on any proposal or plan by the Company or any of its Subsidiaries to engage in any acquisition of assets or stock
(other than in the ordinary course of business) or any financing, merger, consolidation, tender offer, reorganization or similar transaction involving the Company, or any of its Subsidiaries; provided that, in such event, the holders of a
majority of the Investor Registrable Securities to be included in such Demand Registration shall be entitled to withdraw such request and, if such withdrawn request is a Company-Paid Long Form Registration, such Demand Registration shall not count
as one of the permitted Company-Paid Long Form Registrations hereunder and, in all cases, the Company shall pay all Registration Expenses in connection with such registration. The Company may delay a Demand Registration hereunder only once in any
twelve-month period. 
 (f) Selection of Underwriters. The holders of a majority of the Investor Registrable Securities included in
the Demand Registration will have the right to select the investment banker(s) and manager(s) to administer the offering. 
 (g) Other
Registration Rights. Except as provided in this Agreement, the Company shall not grant to any Person the right to request the Company to register equity securities of the Company held by such Person, or any securities convertible or exchangeable
into or exercisable for such securities, without the prior written consent of the holders of 66 2/3% of the Investor Registrable Securities, which consent may be withheld in their sole discretion. 
 2. Piggyback Registrations. 
 (a)
Right to Piggyback. Whenever the Company proposes to register any of its equity securities (including any proposed registration of the Company’s equity securities by any third party) whether or not for sale for its own account (other
than pursuant to a Demand Registration), except for registrations a Form S-4 or S-8 or any successor or similar forms, but including the IPO) and the registration form to be used may be used for the registration of Registrable Securities (a
“Piggyback Registration”), the Company shall give prompt written 

  

 3. 

 
notice to all holders of Registrable Securities of its intention to effect such a registration and shall include in such registration all Registrable
Securities with respect to which the Company has received written requests for inclusion therein within twenty (20) days after the receipt of the Company’s notice (it being understood that no Warrants or other securities convertible into,
or exercisable for, Registrable Securities shall be included in any such registration unless such Warrants or other securities are, or will be in connection with such offering, converted or exercised prior to such registration). 
 (b) Piggyback Expenses. Subject to the qualification set forth in Section 5(b) below, the Registration Expenses of the holders of Registrable
Securities shall be paid by the Company in all Piggyback Registrations. 
 (c) Priority On Primary Registrations. If a Piggyback
Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the
number which can be sold in an orderly manner in such offering within a price range acceptable to the Company without adversely affecting the marketability of such offering, the company shall include in such registration (i) first, the
securities which the Company proposes to sell, (ii) second, the Registrable Securities requested to be included in such registration, pro rata among the holders of such Registrable Securities on the basis of the number of Registrable Securities
owned by each such holder, and (iii) third, any other securities requested to be included in such registration, pro rata among the holders of such securities on the basis of the amount of such securities owned by each such holder. 

(d) Priority On Secondary Registrations. If a Piggyback Registration is an underwritten secondary registration on behalf of any holders of the
company’s securities (other than the holders of Registrable Securities), and the managing underwriters advise the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the number
which can be sold in an orderly manner in such offering within a price range acceptable to the holders of a majority of the securities requesting such registration without adversely affecting the marketability of the offering, the Company shall
include in such registration (i) first, the securities requested to be included therein by the holders requesting such registration, together with Registrable Securities requested to be included in such registration, pro rata among the holders
of such securities on the basis of the number of securities owned by each such holder, and (ii) then, any other securities requested to be included in such registration, pro rata among the holders of such securities on the basis of the amount
of such securities owned by each such holder. 
 (e) Selection of Underwriters. If a Piggyback Registration is an underwritten
offering, the Board will have the right to select the investment banker(s) and manager(s) for the offering. 
 3. Holdback Agreements.

 (a) To the extent not inconsistent with applicable law, each holder of Registrable Securities shall not effect any public sale or
distribution (including sales pursuant to Rule 144) of equity securities of the Company, or any securities, options or rights convertible into or exchangeable or exercisable for such securities, during the period (not to exceed 180 days) (the

  

 4. 

 
“LockUp Period”) prior to and after the effective date of any (x) underwritten Demand Registration (except as part of such underwritten
registration) or (y) underwritten Piggyback Registration (except as part of such underwritten registration or pursuant to registrations on Form S-4 or Form S-8 or any successor form) that is agreed to by the underwriter managing the registered
public offering and the Company (in the case of a Piggyback Registration or any secondary registration) or a majority of the Investor Registrable Securities included in such registration (in the case of a Demand Registration). 
 (b) The Company (i) agrees not to effect any public sale or distribution of its equity securities, or any securities, options or rights convertible
into or exchangeable or exercisable for such securities, during the Lockup Period, (except, to the extent agreed to by the underwriter requesting the Lock Up Period, pursuant to Form S-4 or Form S-8 (or any similar or successor forms)) and
(ii) agrees to use reasonable efforts to cause, to the extent not inconsistent with applicable law, each holder of its equity securities, or any securities, options or rights convertible into or exchangeable or exercisable for equity securities
purchased from the Company at any time after the date of this Agreement that holds more than 2% of the Company’s common equity securities on fully diluted basis (other than in a registered public offering or pursuant to registrations on Form
S-4 or Form S-8) to agree not to effect any public sale or distribution (including sales pursuant to Rule 144) of any such securities during the Lockup Period. 
 4. Registration Procedures. Whenever the holders of Registrable Securities have requested that any Registrable Securities be registered pursuant to this Agreement, the Company shall use its reasonable efforts
to effect the registration and the sale of such Registrable Securities in accordance with the intended method of disposition thereof, and pursuant thereto the Company shall as expeditiously as possible: 
 (a) prepare and file with the Securities and Exchange Commission a registration statement with respect to such Registrable Securities and use its
reasonable efforts to cause such registration statement to become effective (provided that within a reasonable time before filing a registration statement or prospectus or any amendments or supplements thereto, the Company shall furnish to the
counsel selected by the holders of a majority of the Investor Registrable Securities covered by such registration statement copies of all such documents proposed to be filed, which documents shall be subject to the review and comment of such
counsel); 
 (b) notify in writing each holder of Registrable Securities of the effectiveness of each registration statement filed hereunder
and prepare and file with the Securities and Exchange Commission such amendments and supplements to such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for a
period of not less than 180 days and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement during such period in accordance with the intended methods of disposition
by the sellers thereof set forth in such registration statement; 
 (c) furnish to each seller of Registrable Securities such number of
copies of such registration statement, each amendment and supplement thereto, the prospectus included in such registration statement (including each preliminary prospectus) and such other documents as such 

  

 5. 

 
seller may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such seller; 
 (d) use its reasonable efforts to register or qualify such Registrable Securities under such other securities or blue sky laws of such jurisdictions as
any seller reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable - such seller to consummate the disposition in such jurisdictions of the Registrable Securities owned by such seller
(provided that the company shall not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this subparagraph, (ii) subject itself to taxation in any such
jurisdiction or (iii) consent to general service of process in any such jurisdiction); 
 (e) notify each seller of such Registrable
Securities, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, upon discovery that, or upon the discovery of, the happening of any event as a result of which the prospectus included in such
registration statement contains an untrue statement of a material fact or omits any fact necessary to make the statements therein not misleading in light of the circumstances under which they were made, and, at the request of any such seller, the
Company shall prepare and furnish to such seller a reasonable number of copies of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an
untrue statement of a material fact or omit to state any fact necessary to make the statements therein not misleading in light of the circumstances under which they were made; 
 (f) cause all such Registrable Securities to be listed on each securities exchange on which similar securities issued by the company are then listed and,
if not so listed, to be listed on the NASD automated quotation system and, if listed on the NASD automated quotation system, use its best efforts to secure designation of all such Registrable Securities covered by such registration statement as a
NASDAQ “national market system security” within the meaning of Rule 11Aa2-1 of the Securities and Exchange Commission or, failing that, to secure NASDAQ authorization for such Registrable Securities; and, without limiting the generality of
the foregoing, to arrange for at least two market makers; to register as such with respect to such Registrable Securities with the NASD; 
 (g) provide a transfer agent and registrar for all such Registrable Securities and a CUSIP number for all such Registrable Securities not later than the effective date of such registration statement; 
 (h) enter into such customary agreements (including underwriting agreements in customary form) and take all such other actions as the holders of a
majority of the Investor Registrable Securities being sold or the underwriters, if any, reasonably request in order to expedite or facilitate the disposition of such Registrable Securities; 
 (i) make available for inspection by any seller of Registrable Securities, any underwriter participating in any disposition pursuant to such registration
statement and any attorney, accountant or other agent retained by any such seller or underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors,
employees and independent accountants to supply all information 

  

 6. 

 
reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement and assist and, at the
request of any participating underwriter, cause such officers or directors to participate in presentations to prospective purchasers; 
 (j)
otherwise use its reasonable efforts to comply with all applicable rules and regulations of the Securities and Exchange Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the
period of at least twelve (12) months beginning with the first day of the Company’s first full calendar quarter after the effective date of the registration statement, which earnings statement shall satisfy the provisions of
Section 1l(a) of the Securities Act and Rule 158 thereunder; 
 (k) permit any holder of Registrable Securities which holder, in its
sole and exclusive judgment, might be deemed to be an underwriter or a controlling person of the Company, to participate in the preparation of such registration or comparable statement and to require the insertion therein of material, furnished to
the Company in writing, which in the reasonable judgment of such holder and its counsel should be included; 
 (l) in the event of the
issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending or preventing the use of any related prospectus or suspending the qualification of any equity securities included in such registration
statement for sale in any jurisdiction, the company shall use its reasonable efforts promptly to obtain the withdrawal of such order; 
 (m)
use its reasonable efforts to cause such Registrable Securities covered by such registration statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to enable the sellers thereof to
consummate the disposition of such Registrable Securities; and 
 (n) obtain a cold comfort letter from the Company’s independent public
accountants in customary form and covering such matters of the type customarily covered by cold comfort letters as the holders of a majority of the Investor Registrable Securities being sold in such registered offering reasonably request (provided
that such Registrable Securities constitute at least 10% of the securities covered by such registration statement). 
 5. Registration
Expenses 
 (a) all expenses incidental to the Company’s performance of or compliance with this Agreement, including without
limitation all registration and filing fees, fees and expenses of compliance with securities or blue sky laws, printing expenses, filing expenses, travel expenses, messenger and delivery expenses, fees and disbursements of custodians, and fees and
disbursements of counsel for the Company and all independent certified public accountants, underwriters (excluding discounts and commissions) and other Persons retained by the Company and, subject to Section 5(b), the holders of a majority of
the Investor Registrable Securities included in such registration (all such expenses being herein called “Registration Expenses”), shall be borne by the Company, except as otherwise expressly provided in this Agreement, except that
the Company shall, in any event, pay its internal expenses (including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting 

  

 7. 

 
duties), the expense of any annual audit or quarterly review, the expense of any liability insurance and the expenses and fees for listing the securities to
be registered on each securities exchange on which similar securities issued by the Company are then listed or on the NASD automated quotation system (or any successor or similar system). 
 (b) In connection with each demand registration and each Piggyback Registration, the Company shall reimburse the holders of Registrable Securities
included in such registration for the reasonable fees and disbursements of one counsel (in addition to local counsel) chosen by the holders of a majority of the Investor Registrable Securities included in such registration and for the reasonable
fees and disbursements of each additional counsel retained by any holder of Registrable Securities for the purpose of rendering a legal opinion on behalf of such holder in connection with any underwritten Demand Registration or Piggyback
Registration. 
 (c) To the extent Registration Expenses are not required to be paid by the Company, each holder of securities included in
any registration hereunder shall pay those Registration Expenses allocable to the registration of such holder’s securities so included, and any Registration Expenses not so allocable shall be borne by all sellers of securities included in such
registration in proportion to the aggregate selling price of the securities to be so registered. 
 6. Indemnification. 
 (a) The Company agrees to indemnify, to the extent permitted by law, each holder of Registrable Securities, its officers, directors, agents, employees,
members, partners, fiduciaries, and each Person who controls such holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities and expenses caused by any untrue or alleged untrue statement of material fact
contained in any registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein not misleading, except insofar as the same are caused by or contained in any information furnished in writing to the Company by such holder expressly for use therein or by such holder’s failure to deliver a copy of the registration
statement or prospectus or any amendments or supplements thereto after the Company has furnished such holder with a sufficient number of copies of the same. In connection with an underwritten offering, the Company shall indemnify such underwriters,
their officers, directors, agents, employees, members, partners, fiduciaries and each Person who controls such underwriters (within the meaning of the Securities Act) to the same extent as provided above with respect to the indemnification of the
holders of Registrable Securities. 
 (b) In connection with any registration statement in which a holder of Registrable Securities is
participating, each such holder shall furnish to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such registration statement or prospectus and, to the extent permitted by law,
shall indemnify the Company, its directors and officers and each Person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expenses resulting from any untrue or alleged untrue
statement of material fact contained in the registration statement, prospectus or preliminary prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated 

  

 8. 

 
therein or necessary to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in or omitted
from any information or affidavit so furnished in writing by such holder; provided that the obligation to indemnify shall be individual, not joint and several, for each holder and shall be limited to the lesser of (1) the net amount of
proceeds received by such holder from the sale of Registrable Securities pursuant to such registration statement or (2) such holder’s pro rata share (based on ownership of capital stock) of such indemnifiable losses, claims, damages,
liabilities and/or expenses. 
 (c) Any Person entitled to indemnification hereunder shall (i) give prompt written notice to the
indemnifying party of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any Person’s right to indemnification hereunder to the extent such failure has not prejudiced the
indemnifying party) and (ii) unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the
defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent (but
such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified
by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties with respect to such claim.

 (d) The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made by or
on behalf of the indemnified party or any officer, director or controlling Person of such indemnified party and shall survive the transfer of securities and termination of this Agreement. The Company also agrees to make such provisions, as are
reasonably requested by any indemnified party, for contribution to such party in the event the Company’s indemnification is unavailable for any reason. 
 7. Participation in Underwritten Registrations 
 (a) No person may participate in any registration
hereunder which is underwritten unless such Person (i) agrees to sell such person’s securities on the basis provided in any underwriting arrangements approved by the Person or Persons entitled hereunder to approve such arrangements and
(ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements. 
 (b) Each person that is participating in any registration hereunder agrees that, upon receipt of any notice from the Company of the happening of any
event of the kind described in Section 4(e) above, such person will forthwith discontinue the disposition of its Registrable Securities pursuant to the registration statement until such person’s receipt of the copies of a supplemented or
amended prospectus as contemplated by such Section 4(e). In the event the Company shall give any such notice, the applicable time period mentioned in Section 4(b) during which a Registration Statement is to remain effective shall be
extended by the number of days 

  

 9. 

 
during the period from and including the date of the giving of such notice pursuant to this paragraph to and including the date when each seller of a
Registrable Security covered by such registration statement shall have received the copies of the supplemented or amended prospectus contemplated by Section 4(e). 
 8. Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Securities and Exchange Commission that may permit the sale of Registrable Securities to the public
without registration, the Company agrees at all times after the Company has filed a registration statement with the Securities and Exchange Commission pursuant to the requirements of either the Securities Act or the Securities Exchange Act to use
its best efforts to: (a) make and keep public information regarding the Company available as those terms are understood and defined in Rule 144 under the Securities Act; (b) file with the Securities and Exchange Commission in a timely
manner all reports and other documents required of the Company under the Securities Exchange Act at any time after it has become subject to such reporting requirements; and (c) so long as a holder owns any Registrable Securities, furnish to the
holder forthwith upon written request a written statement by the Company as to its compliance with the reporting requirements of Rule 144, and of the Securities Act and the Securities Exchange Act, a copy of the most recent annual or quarterly
report of the Company, and such other reports and documents so filed as a holder may reasonably request in availing itself of any rule or regulation of the Securities and Exchange Commission allowing a holder to sell any such securities without
registration. 
 9. Definitions. 
 (a) “Board” means the board of directors of the Company. 
 (b) “Investor Registrable Securities”
means (i) any Common Stock or Preferred Stock held by a member of an Investor Group (as defined in the Stockholders Agreement) or held by an Additional Party upon the written consent of holders of at least 66 2/3% of the Investor Registrable
Securities and (ii) any other securities issued or issuable with respect to the securities referred to in clause (i) by way of a stock dividend or stock split or in connection with an exchange or combination of shares, recapitalization,
merger, consolidation or other reorganization. 
 (c) “Other Registrable Securities” means (i) any shares of Common
Stock or Preferred Stock held by a Person who is a party to this Agreement that do not constitute Investor Registrable Securities (including, without limitation, any shares of Common Stock or Preferred Stock acquired by a Warrantholder upon exercise
of any of the Warrants issued to or otherwise acquired by such Warrantholder) and (ii) any other securities of the Company issued or issuable with respect to the securities referred to in clause (i) by way of a stock dividend or stock
split or in connection with an exchange or combination of shares, recapitalization, merger, consolidation or other reorganization. 
 (d)
“Public Offering” has the meaning assigned to such term in the stockholders agreement. 
  

 10. 

 (e) “Registrable Securities” means Investor Registrable Securities and Other Registrable
Securities, collectively, provided, however, that in the event that any equity securities are issued which do not participate in the residual equity of the company (“Non- Participating Securities”), such Non-Participating
Securities will not be any type of Registrable Securities. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when they have been transferred to the Company or distributed to the public pursuant to
an offering registered under the Securities Act or sold to the public through a broker, dealer or market maker in compliance with Rule 144 under the Securities Act (or any similar rule then in force). For purposes of this Agreement, a Person shall
be deemed to be a holder of Registrable Securities whenever such person has the right to acquire such Registrable Securities (upon conversion or exercise (including, without limitation, upon exercise of the Warrants), in connection with a transfer
of securities or otherwise, but disregarding any restrictions or limitations upon the exercise of such right), whether or not such acquisition has actually been effected. 
 (f) “Securities Act” means the Securities Act of 1933, as amended from time to time, or any successor federal law then in force. 
 (g) “Securities Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, or any successor federal law then
in force. 
 (h) “Stockholders Agreement” means that certain Amended and Restated Stockholders Agreement, dated as of
December 31, 1998 and amended and restated as of March 23, 2000, by and among the Company and certain of its stockholders named therein, as further amended from time to time in accordance with its terms. 
 (i) “Warrant” has the meaning assigned to such term in the Stockholders Agreement. 
 (j) Unless otherwise stated, other capitalized terms contained herein have the meanings set forth in the Recapitalization Agreement, dated as of
December 24, 1998, by and among HEALTHSOUTH, the Prior Investors and the entities listed on the Schedule of CompHealth Entities attached thereto (the “Recapitalization Agreement”). 
 10. Miscellaneous. 
 (a) No
Inconsistent Agreements. The Company shall not hereafter enter into any agreement with respect to its securities which is inconsistent with or violates the rights granted to the holders of Registrable Securities in this Agreement. 
 (b) Adjustments Affecting Registrable Securities. The Company shall not take any action, or permit any change to occur, with respect to its
securities which would adversely affect the ability of the holders of Registrable Securities to include such Registrable Securities in a registration undertaken pursuant to this Agreement or which would adversely affect the marketability of such
Registrable Securities in any such registration. 
 (c) Remedies. Any Person having rights under any provision of this Agreement shall
be entitled to enforce such rights specifically to recover damages caused by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. The parties 

  

 11. 

 
hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement and that any party may in
its sole discretion apply to any court of law or equity of competent jurisdiction (without posting any bond or other security) for specific performance and for other injunctive relief in order to enforce or prevent violation of the provisions of
this Agreement. 
 (d) Amendments and Waivers. Except as otherwise provided herein, the provisions of this Agreement may be amended or
waived only upon the prior written consent of the Company and holders of at least 66 2/3% of the Investor Registrable Securities, provided that no amendment or waiver having a material adverse effect on any holder of Registrable Securities
shall be effective against such holder without such holder’s prior written consent. 
 (e) Additional Parties. The Board shall be
entitled, but not obligated, to allow any purchaser of Common Stock (or Warrants or other securities or rights convertible or exercisable into Common Stock) directly from the Company to execute a counterpart of this Agreement and become a party
hereto (each, an “Additional Party”), in which case the Common Stock issued or issuable to any such Additional Party shall be deemed “Other Registrable Securities”, or, if such Person is a member of an Investor Group (as
defined in the Stockholders Agreement) or upon the written consent of holders of at least 66 2/3% of the Investor Registrable Securities, “Investor Registrable Securities” for purposes of this Agreement. Except as set forth in this
Section 10(e) and in Section 1(g), the Company will not grant to any other Persons any registration rights. 
 (f) Successors and
Assigns. All covenants and agreements in this agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and permitted assigns of the parties hereto whether so expressed or not. In
addition, whether or not any express assignment has been made, the provisions of this Agreement which are for the benefit of purchasers or holders of any type of Registrable Securities are also for the benefit of, and enforceable by, any subsequent
holder of Registrable Securities of such type. Notwithstanding the foregoing, in order to obtain the benefit of this agreement, any subsequent holder of Registrable Securities must execute a counterpart signature page to this agreement, thereby
agreeing to be bound by the terms hereof. 
 (g) Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement. 
 (h) Counterparts. This Agreement may be executed
simultaneously in two or more counterparts, any one of which need not contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement. 
 (i) Descriptive Headings. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this
Agreement. 
 (j) Governing Law. The corporate law of Delaware shall govern all issues and questions concerning the relative rights of
the Company and its stockholders. All other issues 

  

 12. 

 
and questions concerning the construction, validity, interpretation and enforcement of this Agreement and the exhibits and schedules hereto shall also be
governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the
application of the laws of any jurisdiction other than the State of Delaware. 
 (k) Notices. All notices, demands or other
communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient, one business day after being sent to the recipient
by reputable overnight courier service (charges prepaid) or on the date of actual receipt if mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid. Such notices, demands and other communications shall
be sent to each holder of Registrable Securities at the address listed for such holder in the books and records of the Company and to the Company at the address of its corporate headquarters or to such other address or to the attention of such other
person as the recipient party has specified by prior written notice to the sending party. 
 (l) Termination. This Agreement shall
terminate with respect to any holder of Registrable Securities on the date on which all Registrable Securities held by such holder may immediately be sold under Rule 144 under the Securities Act during any three-month period, so long as a Lock-Up
Period is not then in effect (in which case this Agreement shall terminate with respect to such holder when such Lock-up Period terminates). 
 (m) Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and restated herein. Such amendment and restatement is effective upon the execution of the Agreement by the Company and holders
of Registrable Securities in accordance with the Prior Agreement. Upon such execution, all provisions of, rights granted and covenants made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further
force or effect. HEALTHSOUTH hereby acknowledges that upon the effectiveness of this Agreement, HEALTHSOUTH shall have no further rights pursuant to the Prior Agreement and any and all such rights shall have no further force or effect. 

 

 13. 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Registration Rights
Agreement as of the date first written above. 
  

			
	 COMPHEALTH GROUP, INC.

		
	By:	 	

	Its:	 	CFO
	
	 HEALTHSOUTH CORPORATION

		
	By:	 	  
	Its:	 	  

  

 14. 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Registration Rights
Agreement as of the date first written above. 
  

			
	 COMPHEALTH GROUP, INC.

		
	By:	 	  
	Its:	 	  
	
	 HEALTHSOUTH CORPORATION

		
	By:	 	

	Its:	 	EVP

  

 14. 

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

			
	 NASSAU CAPITAL PARTNERS II L.P.

	By:	 	Nassau Capital II L.L.C., its general partner
		
	By:	 	

	Its:	 	  
	
	 NAS PARTNERS L.L.C.

		
	By:	 	

	Its:	 	  

  

 15. 

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

			
	 NEW ENTERPRISE ASSOCIATES VIII,
 LIMITED
PARTNERSHIP

		
	By:	 	NEA Partners VIII, Limited Partnership
	Its:	 	General Partner
		
	By:	 	

	Its:	 	General Partner
	
	NEA PRESIDENTS FUND, L.P.
		
	By:	 	NEA Presidents Partners, L.P.
	Its:	 	General Partner
		
	By:	 	

	Its:	 	General Partner
	
	NEA VENTURES 1998, L.P.
		
	By:	 	

	Its:	 	Vice President
	
	NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP
	By:	 	 NEA Partners 10, Limited Partnership
its General Partner

		
	By:	 	

		 	 General Partner

	
	NEW ENTERPRISE ASSOCIATES 8A, LIMITED PARTNERSHIP
	By:	 	 NEA Partners 10, Limited Partnership
its General Partner

		
	By:	 	

		 	 General Partner

	
	  
	Charles Linehan

  

 16. 

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

			
	 NEW ENTERPRISE ASSOCIATES VIII,
 LIMITED
PARTNERSHIP

		
	By:	 	NEA Partners VIII, Limited Partnership
	Its:	 	General Partner
		
	By:	 	  
	Its:	 	  
	
	NEA PRESIDENTS FUND, L.P.
		
	By:	 	NEA Presidents Partners, L.P.
	Its:	 	General Partner
		
	By:	 	  
	Its:	 	  
	
	NEA VENTURES 1998, L.P.
		
	By:	 	  
	Its:	 	  
	
	NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP
	By:	 	NEA Partners 10, Limited Partnership
		 	 its General Partner

		
	By:	 	  
		 	General Partner
	
	NEW ENTERPRISE ASSOCIATES 8A, LIMITED PARTNERSHIP
	By:	 	NEA Partners 10, Limited Partnership
		 	 its General Partner

		
	By:	 	  
		 	General Partner
	
	

	Charles Linehan

  

 16. 

 [SIGNATURE PAGE TO AMENDED AND 
 RESTATED REGISTRATION RIGHTS AGREEMENT] 
  

			
	Acacia Venture Partners, L.P.
	By:	 	Acacia Management, L.P., It’s General Partner
		
	By:	 	

		 	C. Sage Givens, General Partner
	
	South Pointc Venture Partners, L.P.
		
	By:	 	

	C. Sage Givens, General Partner

  

 17. 

 [SIGNATURE PAGE TO AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

	
	
	

	Michael Weinholtz
	
	   
	Sean Dailey

  

 18. 

 [SIGNATURE PAGE TO AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

	
	
	   
	Michael Weinholtz
	
	

	Sean Dailey

 18. 

 [SIGNATURE PAGE TO AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

					
	NEW YORK LIFE INSURANCE COMPANY
		
	BY:	 	

		 	Name:	 	Anthony R. Malloy
		 	Title:	 	Investment Vice President

  

 19. 

 [SIGNATURE PAGE TO AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

			
	 Frazier Healthcare IV, L.P.
 By FHM
IV, LP, its general partner
 By FHM IV, LLC, its general partner

		
	 By
	 	

		 	 Nader Naini, Member

	
	 Frazier Affiliates IV, L.P.
 By FHM
IV, LP, its general partner
 By FHM IV, LLC, its general partner

		
	 By
	 	  
		 	 Nader Naini, Member

  

 20. 

 [SIGNATURE PAGE TO AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

			
	 Frazier Healthcare IV, L.P.
 By FHM IV, LP, its general partner
 By FHM IV, LLC, its general partner

		
	 By
	 	  
		 	 Nader Naini, Member

	
	 Frazier Affiliates IV, L.P.
 By FHM IV, LP, its general partner
 By FHM IV, LLC, its general partner

		
	 By
	 	

		 	 Nader Naini, Member

  

 20. 

 [SIGNATURE PAGE TO AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT] 
  

			
	 PROSPECT VENTURE PARTNERS II, L.P.

		
	 By:
	 	 Prospect Management Co. II, LLC, its General Partner

		
	 By:
	 	

		 	 James Tananbaum
 Managing Member

	
	 PROSPECT ASSOCIATES II, L.P.

		
	 By:
	 	 Prospect Management Co. II, LLC, its General Partner

		
	 By:
	 	

		 	 James Tananbaum
 Managing Member

  

 21. 

 SCHEDULE OF INVESTORS 
 Nassau Capital Partners II L.P. 
 NAS Partners I L.L.C. 
 Acacia Venture Partners, L.P. 
 South Pointe
Venture Partners, L.P. 
 New Enterprise Associates, Limited Partnership 
 New Enterprise Associates VIII, Limited Partnership 
 NEA Ventures 1998, L.P.

 NEA Presidents Fund, L.P. 
 New
Enterprise Associates 10, Limited Partnership 
 New Enterprise Associates 8A, Limited Partnership 
 Charles Linehan 
 Frazier Healthcare IV, L.P.

 Frazier Affiliates IV, L.P. 
 Acacia Venture Partners II, L.P. 
 South Pointe Venture Partners, L.P. 
 Prospect Venture Partners II, L.P. 
 Prospect Associates II, L.P. 

 SCHEDULE OF WARRANTHOLDERS 
 New York Life Insurance Company 

 SCHEDULE OF OTHER STOCKHOLDERS 
 Michael Weinholtz 
 Sean DaileySecond Amended and Restated Stockholders Agreement

 Exhibit 10.15 
 COMPHEALTH GROUP, INC. 
 SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT 
 THIS
SECOND AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is entered into as of March 25, 2003, by and among CompHealth Group, Inc., a Delaware corporation formerly known as CMS Capital Ventures, Inc. (the
“Company”). HEALTHSOUTH Corporation, a Delaware corporation (“HEALTHSOUTH”), each of the investors from time to time listed on the Schedule of Investors attached hereto (collectively, the
“Investors” and each individually, an “Investor”), each of the Executives listed from time to time on the Schedule of Executives attached hereto (collectively, the “Executives” and each
individually, an “Executive”), and each of the warrantholders listed from time to time on the Schedule of Warrantholders attached hereto (collectively, the “Warrantholders” and each individually, a
“Warrantholder”). The Investors, the Executives and the Warrantholders are collectively referred to herein as the “Stockholders” and each individually as a “Stockholder.” Capitalized terms used but
not otherwise defined herein are defined in Section 11 hereof. 
 Certain of the Investors and HEALTHSOUTH (collectively, the
“Prior Investors”) hold shares of the Company’s common stock, par value $.01 per share (the “Common Stock”), and the Company’s preferred stock, par value $.01 per share (the “Preferred Stock”). The Executives
will purchase shares of Common Stock from time to time upon exercise of options issued to such Executives pursuant to the 1998 Stock Option Plan or any successor stock option plan (the “Stock Option Plan”). 
 Certain of the Investors are purchasing shares of the Common Stock and Preferred Stock (i) from HEALTHSOUTH pursuant to that certain Stock Purchase
Agreement dated as of the date hereof, (ii) from Nassau Capital Partners II L.P. and NAS Partners I L.L.C. pursuant to that certain Stock Purchase Agreement dated as of the date hereof or (iii) from the Company pursuant to that certain
Stock Purchase Agreement dated as of the date hereof (collectively, the “Purchase Agreements”), and the obligations in the Purchase Agreements are conditioned upon the execution and delivery of this Agreement. 
 The Company, the Prior Investors, the Executives and the Warrantholders (collectively, the “Prior Stockholders”) are parties to an
Amended and Restated Stockholders Agreement made as of December 31, 1998 and amended and restated as of March 23, 2000 (the “Prior Agreement”). The parties to the Prior Agreement desire to amend and restate the Prior
Agreement and accept the rights and covenants hereof in lieu of their rights and covenants under the Prior Agreement. 
  

 1. 

 NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement, intending to be legally bound, hereby agree as follows: 
 1. Board of Directors. 
 (a) From and after the date hereof and until the provisions
of this Section 1 cease to be effective, each Stockholder shall vote all of his or its Stockholder Shares and any other voting securities of the Company over which such Stockholder has voting control and shall take all other necessary or desirable
actions within his or its control (whether in the capacity as a stockholder, director, member of a board committee or officer of the Company or otherwise, and including, without limitation, attendance at meetings in person or by proxy for purposes
of obtaining a quorum and execution of written consents in lieu of meetings), and the Company shall take all necessary and desirable actions within its control (including, without limitation, calling special board and stockholder meetings), so that:

 (i) the authorized number of directors on the Company’s board of directors (the “Board”) shall be
established at seven (7) directors, or such greater number as is approved by a Supermajority Vote of the Stockholders; 
 (ii)
the following persons shall be elected to the Board: 
 (A) (1) one (1) representative designated by Stockholders
holding a majority of the shares of Common Stock within the Nassau Group (so long as such group is a Qualifying Investor Group); (2) one (1) representative designated by Stockholders holding a majority of the shares of Common Stock within the
Acacia Group (so long as such group is a Qualifying Investor Group); (3) one (1) representative designated by Stockholders holding a majority of the shares of Common Stock within the Frazier Group (so long as such group is a Qualifying
Investor Group); (4) one (1) representative designated by Stockholders holding a majority of the shares of Common Stock within the NEA Group (so long as such group is a Qualifying Investor Group); and (5) one (1) representative
(in addition to the representative designated pursuant to the preceding clause (4)) designated by Stockholders holding a majority of the shares of Common Stock within the NEA Group so long as the NEA Group holds collectively at least 25% of the
aggregate Common Stock (on a fully diluted basis) (collectively, the “Investor Directors”); 
 (B) the
Company’s chief executive officer (the “Executive Director”) (who shall initially be Michael Weinholtz); 
 (C) one (1) representative that is designated by a Supermajority Vote of the Stockholders and approved by the Executive Director (the “Outside Director”); provided that no such Outside Director shall be a member
of the Company’s or any Investor’s management or an employee or officer of the Company, any Investor or any of their respective Affiliates; and 
 (D) if the authorized number of directors on the Board is increased to a number greater than seven (7) in accordance with 

  

 2. 

 
subsection (i) above, any additional directors shall be representatives that are designated by a Supermajority Vote of the Stockholders (each, a
“Non-Investor Director”); provided that no such Non-Investor Director shall be a member of any Investor’s management or an employee or officer of any Investor or any Affiliate of an Investor; 
 (iii) except with respect to CHG Marketing and Technologies Corp., the composition of the board of directors of each of the Company’s
subsidiaries (each, a “Sub Board”) shall be the same as that of the Board; 
 (iv) if the Board or any Sub
Board forms one or more committees of the Board or such Sub Board, such committee shall, in each case, include at least one Investor Director; 
 (v) the removal from the Board or a Sub Board (with or without cause) of any Investor Director, the Executive Director, any Outside Director or any Non-Investor Director shall be only upon the written request of the
Person or Persons originally entitled to designate such director pursuant to Section 1(a)(ii) above; provided that if the Executive Director ceases to be an employee of the Company and its subsidiaries, he shall be removed as a director
promptly after his employment ceases on a date specified by the Supermajority Vote of the Stockholders; provided further that, if any Person or Persons entitled to designate a director pursuant to Section 1(a)(ii) above ceases to have
the right to designate such director, such director shall be removed promptly after such Person or Persons cease to have the right to designate such director; and 
 (vi) in the event that any representative designated hereunder for any reason ceases to serve as a member of the Board or a Sub Board
during his or her term of office, the resulting vacancy on the Board or the Sub Board shall be filled by a representative designated by the Person or Persons originally entitled to designate such director pursuant to Section 1(a)(ii) above (so long
as such Person or Persons continue to be entitled to designate a director pursuant to Section 1(a)(ii) above); provided that, if such Person or Persons are no longer entitled to designate a director pursuant to Section 1(a)(ii) above,
such vacancy shall be filled by a representative designated by a Supermajority Vote of the Stockholders. 
 (b) There shall be
at least four (4) meetings of the Board during every fiscal year, and at least one meeting shall be held in each calendar quarter during the Company’s fiscal year. The Company shall pay all out-of-pocket expenses incurred by each director
in connection with attending regular and special meetings of the Board, any Sub Board and any committee thereof. 
 (c) If any
party fails (but is otherwise entitled) to designate a representative to fill a directorship pursuant to the terms of this Section 1, such directorship shall not be filled and the number of directors shall be reduced accordingly;
provided that the parties shall take all necessary actions to increase the Board and elect such representative if the party or parties which failed (and are otherwise entitled) to designate such a representative so directs. 
  

 3. 

 (d) The provisions of this Section 1 shall terminate automatically and be of no
further force and effect upon a Qualified Public Offering. 
 (e) Notwithstanding anything herein to the contrary, no
Warrantholder (except, in the case of any Warrantholder, with respect to any shares of Common Stock issued upon the exercise of the Warrants, and only so long as such shares in the aggregate represent 5% or more of any class of outstanding
Stockholder Shares on a fully diluted basis) shall be required to vote its Stockholder Shares or any other voting securities of the Company over which it has voting control in accordance with this Section 1 and no Warrantholder (except to the
extent provided in the immediately preceding parenthetical) shall be a party to this Section 1 for purposes of voting such shares in accordance with Section 1(a)(ii). 
 2. Irrevocable Proxy; Conflicting Agreements. 
 (a) In order to secure each Executive’s obligation to vote his or her Stockholder Shares and other voting securities of the Company in accordance with the provisions of Sections 1, 7 and 8 hereof, each Executive
hereby appoints a representative to be elected from time to time by the Investors holding at least 66 2/3% of the Common Stock held by all Investors (which shall initially be Thomas C. Barnds) as his or her true and lawful proxy and
attorney-in-fact, with full power of substitution, to vote all of his or her Stockholder Shares and other voting securities of the Company for the election and/or removal of directors and all such other matters as expressly provided for in Sections
1, 7 and 8 hereof. Such representative may exercise the irrevocable proxy granted to him hereunder at any time such Executive fails to comply with the provisions of this Agreement, and shall vote all securities with respect to which he is exercising
his proxy in the same manner and in the same proportion as the Investors. The proxies and powers granted by each Executive pursuant to this Section 2 are coupled with an interest and are given to secure the performance of such Executive’s
obligations to the Investors under this Agreement. Such proxies and powers will be irrevocable for the term of this Agreement and will survive the death, incompetency or disability of such Executive and the respective holders of his or her
Stockholder Shares and other voting securities of the Company. 
 (b) Each Stockholder represents that he or it has not
granted and is not a party to any proxy, voting trust or other agreement which is inconsistent with or conflicts with the provisions of this Agreement, and no holder of Stockholder Shares shall grant any proxy or become party to any voting trust or
other agreement which is inconsistent with or conflicts with the provisions of this Agreement. 
 3. Financial Statements And Other
Information. The Company shall deliver the following to the Stockholder of each Investor Group which holds the largest number of Stockholder Shares (so long as such Investor Group holds any Stockholder Shares), to each holder of at least 10% of
the outstanding Stockholder Shares of any class (on a fully-diluted basis) and to the designee of the Warrantholders; provided, however, that the Company shall have no obligation to make any such delivery if the Stockholders waive such
delivery requirements by Supermajority Vote: 
 (a) as soon as available but in any event within 30 days after the end of each
monthly accounting period in each fiscal year, unaudited consolidated statements of 

  

 4. 

 
income and cash flows of the Company and its subsidiaries for such monthly period and for the period from the beginning of the fiscal year to the end of such
month, and an unaudited consolidated balance sheet of the Company and its subsidiaries as of the end of such monthly period, setting forth in each case comparisons to the Company’s annual budget and to the corresponding period in the preceding
fiscal year, and all such statements shall be prepared in accordance with generally accepted accounting principles, consistently applied, subject to the absence of footnote disclosures and to normal year-end adjustments for recurring accruals, and
shall be certified by the Company’s chief financial officer; 
 (b) within 90 days after the end of each fiscal year,
consolidated statements of income and cash flows of the Company and its subsidiaries for such fiscal year, and consolidated balance sheets of the Company and its subsidiaries as of the end of such fiscal year, setting forth in each case comparisons
to the Company’s annual budget and to the preceding fiscal year, all prepared in accordance with generally accepted accounting principles, consistently applied, and accompanied by (a) an opinion containing no exceptions or qualifications
(except for qualifications regarding specified contingent liabilities) of an independent accounting firm of recognized national standing, (b) a certificate from such accounting firm, addressed to the Company’s board of directors, stating
that in the course of its examination nothing came to its attention that caused it to believe that there was any default by the Company or any subsidiary thereof in the fulfillment of or compliance with any of the terms, covenants, provisions or
conditions of any other material agreement to which the Company or any subsidiary is a party or, if such accountants have reason to believe any default by the Company or any subsidiary thereof exists, a certificate specifying the nature and period
of existence thereof, and (c) a copy of such firm’s annual management letter to the Board; 
 (c) promptly upon
receipt thereof, any additional reports, management letters or other detailed information concerning significant aspects of the Company’s operations or financial affairs given to the Company by its independent accountants (and not otherwise
contained in other materials provided hereunder); 
 (d) at least 30 days but not more than 90 days prior to the beginning of
each fiscal year, an annual budget prepared on a monthly basis for the Company and its subsidiaries for such fiscal year (displaying anticipated statements of income and cash flows and balance sheets), and promptly upon preparation thereof any other
significant budgets prepared by the Company and any revisions of such annual or other budgets, within 30 days after any monthly period in which there is a material adverse deviation from the annual budget, a letter from the Company’s chief
executive officer or chief financial officer explaining the deviation and what actions the Company has taken and proposes to take with respect thereto; 
 (e) promptly (but in any event within five (5) business days) after the discovery or receipt of notice of any default under any material agreement to which it or any of its subsidiaries is a party or any other
material adverse change, event or circumstance affecting the Company or any subsidiary thereof (including, without limitation, the filing of any material litigation against the Company or any subsidiary thereof or the existence of any dispute with
any Person which involves a reasonable likelihood of such litigation being commenced), a letter from the Company’s chief executive officer or chief financial officer specifying the nature and period 

  

 5. 

 
of existence thereof and what actions the Company and its subsidiaries have taken and propose to take with respect thereto; 
 (f) within ten (10) days after transmission thereof, copies of all financial statements, proxy statements, reports and any other
general written communications which the Company sends to its stockholders and copies of all registration statements and all regular, special or periodic reports which it files, or any of its officers or directors file with respect to the Company,
with the Securities and Exchange Commission or with any securities exchange on which any of its securities are then listed, and copies of all press releases and other statements made available generally by the Company to the public concerning
material developments in the Company’s and its subsidiaries’ businesses; and 
 (g) with reasonable promptness, such
other information and financial data concerning the Company and its subsidiaries as any Person entitled to receive information under this Section 3 may reasonably request. 
 Each of the financial statements referred to in Section 3(a) and 3(b) above shall fairly present the financial condition and results of operation of
the Company as of the dates and for the periods stated therein, subject in the case of the unaudited financial statements to changes resulting from normal year-end adjustments for recurring accruals (none of which would, alone or in the aggregate,
be a materially adverse to the financial condition, operating results, assets, operations or business prospects of the Company and its subsidiaries taken as a whole). 
 Except as otherwise required by law or judicial order or decree or by any governmental agency or authority, each Person entitled to receive information regarding the Company and its subsidiaries under this
Section 3 or under Section 4 shall use its best efforts to maintain the confidentiality of all nonpublic information obtained by it hereunder which the Company has reasonably designated as proprietary or confidential in nature;
provided that each such Person may, to the extent necessary, disclose such information in connection with the sale or transfer of any Stockholder Shares, if such Person’s transferee agrees in writing to be bound by the provisions hereof.

 4. Inspection of Property. The Company shall permit any representatives designated by any Investor Group (so long as such Investor
Group holds any Stockholder Shares) or any holder of at least 10% of the outstanding Stockholder Shares of any class upon reasonable notice and during normal business hours to (i) visit and inspect any of the properties of the Company and its
subsidiaries, (ii) examine the corporate and financial records of the Company and its subsidiaries and make copies thereof or extracts therefrom and (iii) discuss the affairs, finances and accounts of any such corporations with the
directors, officers, key employees and independent accountants of the Company and its subsidiaries. The presentation of an executed copy of this Agreement by any member of an Investor Group or any such holder of Stockholder Shares to the
Company’s independent accountants shall constitute the Company’s permission to its independent accountants to participate in discussions with such Persons. 
 5. Restrictions on Transfer. 
 (a) [Reserved] 
  

 6. 

 (b) Transfer of Stockholder Shares. No Stockholder shall Transfer any interest in
any Stockholder Shares or any Warrants, except pursuant to (i) Section 5(e), (ii) Section 7 below, or (iii) a Public Sale (each, an “Exempt Transfer”) without first complying with this Section 5(b) and
Sections 5(c) and 5(d) below to the extent that such sections apply to sales by such Stockholder. Prior to making any Transfer (other than an Exempt Transfer), the transferring Stockholder (the “Transferring Stockholder”) shall
deliver written notice of the proposed Transfer (the “Offer Notice”) to the Company and each of the Investors and other Tag-Along Stockholders. The Offer Notice shall disclose in reasonable detail the proposed class and number of
Stockholder Shares to be transferred or, in the case of a Transfer of Warrants, the class and number of Stockholder Shares issuable upon exercise of such Warrants, the proposed terms and conditions of the Transfer and the identity of the prospective
transferree(s) (if known). No Stockholder shall consummate any Transfer until forty (40) days after the Offer Notice has been given to the Company and to each of the Investors, unless the parties to the Transfer have been finally determined
pursuant to this Section 5 prior to the expiration of such 40-day period (the “Election Period”). The date of the first to occur of such events is referred to herein as the “Authorization Date”. 
 (c) First Offer Rights. First, the Company may elect to purchase all (but not less than all) of the Stockholder Shares or Warrants,
as the case may be, specified in the Offer Notice at the price and on the same terms and conditions as those set forth in the Offer Notice by delivering a written notice of such election to the Transferring Stockholder and each Investor Group within
twenty (20) days after the Offer Notice has been delivered to the Company. If the Company has not elected to purchase all Stockholder Shares or Warrants to be transferred within such twenty-day period, the Investor Groups may elect to purchase
in the aggregate all (but not less than all) of the Stockholder Shares or Warrants, as the case may be, to be transferred (as applicable, the “Available Shares” or “Available Warrants”) at the price and on the same
terms and conditions as those set forth in the Offer Notice by delivering written notice of such election to the Transferring Stockholder within thirty (30) days after the Offer Notice has been delivered to the Investor Groups. In the event
that the Investor Groups in the aggregate elect to purchase more than the Available Shares or Available Warrants, as the case may be, then the number of Available Shares or Available Warrants to be purchased by each Investor Group that has elected
to purchase more than its pro rata share of Available Shares or Available Warrants (based upon the number of Stockholder Shares (excluding Preferred Stock) held by all such Investor Groups) shall be reduced on a pro rata basis in proportion to the
number of Stockholder Shares (excluding Preferred Stock) held by all Investor Groups that have elected to purchase more than their pro rata share that are not owned by such holder. Each Investor Group shall allocate the Stockholder Shares or
Warrants so purchased among the Stockholders comprising such Investor Group pro rata according to the aggregate number of shares of such class of Stockholder Shares, or, in the case Warrants are purchased, according to the aggregate number of shares
of the class of Stockholder Shares into which such Warrants are exercisable, held by each such Stockholder (on a fully diluted basis) or in such other manner as the Stockholders comprising such Investor Group shall from time to time agree. To the
extent that the Company or the Investor Groups have not elected to purchase in the aggregate all of the Stockholder Shares or Warrants specified in the Offer Notice, the Transferring Stockholder may Transfer such Stockholder Shares or Warrants, as
the case may be, to one or more third parties, subject to the provisions of Sections 5(d) and 5(f) below, at a price no less than the price per share or per Warrant, as applicable, specified in the Offer Notice and on terms no more favorable 

  

 7. 

 
to the transferee(s) thereof than the terms offered to the Company and the Investor Groups in the Offer Notice during the 60-day period immediately following
the Authorization Date. Any Stockholder Shares or Warrants not transferred within such 60-day period shall be reoffered to the Company and the Investor Groups under this Section 5(c) prior to any subsequent Transfer (that is subject to this
Section 5(c)). If the Company or any of the Investor Groups have elected to purchase Stockholder Shares or Warrants hereunder, the Transfer of such shares or Warrants to the Company or the Investor Groups, as the case may be, shall be
consummated as soon as practical after the delivery of the election notice(s) to the Transferring Stockholder, but in any event within fifteen (15) days after the expiration of the Election Period (it being understood that, if such Transfer to
the Company or the Investor Groups, as the case may be, is not consummated within such 15-day period (other that as the result of actions or failures to act on the part of the Transferring Stockholder), the Transferring Stockholder shall be
permitted to Transfer such Stockholder Shares or Warrants to one or more third parties during the 60-day period commencing on the 16th day after the end of the Election Period on terms no more favorable to such transferee(s) than the terms offered to the Company and the Investor Groups pursuant to this Section 5(c)). 
 (d) Participation Rights. At least forty (40) days prior to any Transfer of Stockholder Shares (other than pursuant to a
Public Sale or a Transfer to the Company or an Investor Group pursuant to Section 5(c) above and specifically excluding the Warrants and any Exempt Transfer), the Transferring Stockholder shall deliver a written notice (the “Sale
Notice”) to the Company and each of the Tag-Along Stockholders (as defined below), specifying in reasonable detail the class and number of Stockholder Shares to be transferred, the proposed terms, and conditions of the proposed Transfer and
the identity of the prospective transferee(s) (which notice may be the same notice and given at the same time as the Offer Notice under Section 5(c) above where applicable). If neither the Company nor the Investor Groups have elected to purchase all of the Stockholder Shares specified in the Sale Notice, each member of each Investor Group, each
Qualifying Executive and each Warrantholder which holds Stockholder Shares of the class to be transferred or, in the case of any Warrantholder, holds Warrants exercisable for the class of shares to be transferred (collectively, the
“Tag-Along Stockholders”), may elect to participate in the contemplated Transfer by delivering written notice (the “Tag-Along Notice”) to the Transferring Stockholder and the Company within 35 days after receipt by
the Stockholders of the Sale Notice. If any Tag-Along Stockholder in addition to the Transferring Stockholder has elected to participate in such Transfer, the Transferring Stockholder and each such electing Tag-Along Stockholder shall be entitled to
sell in the contemplated Transfer, at the same price per share and on the same terms, a number of Stockholder Shares of such class equal to the product of (i) the quotient determined by dividing the percentage of
Stockholder Shares of such class held by such Person (assuming the exercise of all Warrants) by the aggregate percentage of Stockholder Shares of such class owned by the Transferring Stockholder and the Tag-Along Stockholders participating in such
Transfer (assuming the exercise of all Warrants) and (ii) the number of Stockholder Shares of such class to be sold in the contemplated Transfer. Notwithstanding the foregoing, in the event that the Transferring Stockholder intends to Transfer
more than one class of Stockholder Shares, each Tag-Along Stockholder participating in such Transfer shall be required to sell in the contemplated Transfer a pro rata portion of Stockholder Shares of all such classes (to the extent such Tag-Along
Stockholder owns any shares of such other classes of Stockholder Shares or 

  

 8. 

 
Warrants exercisable for shares of such other classes of Stockholder Shares), which portion shall be determined in the manner set forth immediately above.

 For example, if the Sale Notice contemplated a sale of 100 shares of Common Stock by the Transferring Stockholder, and if the
Transferring Stockholder at such time owns 30% of all shares of Common Stock and if one Tag-Along Stockholder elects to participate and owns 20% of all shares of Common Stock, the Transferring Stockholder would be entitled to sell 60 shares (30%
÷ 50% x 100 shares) and the Tag-Along Stockholder would be entitled to sell 40 shares (20% ÷ 50% x 100 shares). 
 The Transferring Stockholder
shall use best efforts to obtain the agreement of the prospective transferee(s) to the participation of the Tag-Along Stockholders in the contemplated Transfer, and no Transferring Stockholder shall Transfer any Stockholder Shares to any prospective
transferee(s) if such transferee(s) refuses to allow the participation of the Tag-Along Stockholders, unless the Transferring Stockholder offers to purchase from each Tag-Along Stockholder (immediately following the Transferring
Stockholder’s Transfer to such transferee(s)), such number and class of Stockholder Shares as the given Tag-Along Stockholder elected to sell in the Transfer pursuant to this Section 5(d), in each case on the same terms and conditions as
the Transferring Stockholder transferred its Stockholder Shares. 
 Any Tag-Along Stockholder participating in the contemplated Transfer which does not hold
enough Stockholder Shares of a particular class to cover the number of Stockholder Shares of such class which such Tag-Along Stockholder proposes to include in such Transfer but which holds Warrants exercisable for additional Stockholder Shares of
such class shall, as a condition to participating in such Transfer, exercise its Warrants for a number of Stockholder Shares of such class equal to the number of Stockholder Shares of such class being Transferred by such Tag-Along Stockholder
pursuant to this Section 5(d) less the number of Stockholder Shares of such class which such Tag-Along Stockholder holds and intends to include in the Transfer (it being understood that, if such Transfer is not consummated, such Tag-Along
Stockholder shall be entitled to rescind its exercise and to receive replacement Warrants for the Warrants exercised in anticipation of such Transfer). 
 (e) Certain Permitted Transfers. The restrictions contained in this Section 5 shall not apply with respect to Transfers of Stockholder Shares or Warrants (i) in the case of an Executive, (A) by
will or pursuant to applicable laws of descent and distribution and among Executive’s family group, or (B) to the Company upon a repurchase of such Stockholder Shares by the Company in accordance with any of the Company’s stock option
plans and any stock option agreement thereunder, (ii) in the case of an Investor or a Warrantholder, among its Affiliates and (iii) in the case of any Warrantholder, in connection with (A) any Transfer to any other Lender under the
Credit Agreement (as hereinafter defined) or (B) any Transfer deemed necessary to comply with any requirement of law, regulation or order or request from a regulatory authority; provided that such restrictions shall continue to be
applicable to Stockholder Shares or Warrants, as the case may be, after any such Transfer and the transferees of such Stockholder Shares or Warrants (“Permitted Transferees”) shall have agreed in writing to be bound by the
provisions of this Agreement. An Executive’s “family group” means such executive’s spouse and descendants (whether natural or adopted) and any trust solely for the 

  

 9. 

 
benefit of such Executive and/or such executive’s spouse and/or descendants. Notwithstanding the foregoing, no party hereto shall avoid the provisions
of this Agreement by making one or more Transfers to one or more Permitted Transferees and then disposing of all or any portion of such party’s interest in any such Permitted Transferee. 
 (f) Recapitalization Treatment. Notwithstanding anything contained in this Section 5 to the contrary, in connection with any
Transfer of Stockholder Shares (other than shares received upon the exercise of the Warrants) by a Stockholder (or a Permitted Transferee) in accordance with the terms and conditions contained in this Agreement (other than pursuant to Section 7
below prior to a Public Offering), such Stockholder (or such Permitted Transferee) shall cause to be provided to the Stockholder of each Investor Group holding the largest number of Stockholder Shares such information as is necessary for each such
Stockholder to be satisfied in its sole discretion that, after giving effect to such Transfer, the transactions contemplated hereby and in the other Transaction Documents, when viewed collectively, shall continue to qualify as a recapitalization for
accounting purposes and each such Stockholder shall have received such opinions and advice as it deems necessary from the Company’s accountants and advisers as to such recapitalization treatment. No Stockholder (or Permitted Transferee) shall
Transfer any Stockholder Shares unless and until all conditions set forth in the preceding sentence are satisfied to the satisfaction of the Stockholder of each Investor Group holding the largest number of Stockholder Shares in its sole discretion.

 (g) Termination of Restrictions. The restrictions on the Transfer of Stockholder Shares and Warrants set forth in
this Section 5 shall continue with respect to each Stockholder Share and each Warrant following any Transfer thereof (other than pursuant to a Public Sale or a Sale of the Company); provided that in any event such restrictions shall
terminate on the first to occur of a Sale of the Company or (other than with respect to the Executives) a Qualified Public Offering and, with respect to the Executives, 15 months following a Qualified Public Offering. 
 6. Legend. Each certificate evidencing Stockholder Shares or Warrants and each certificate issued upon exercise of the Warrants or in exchange for
or upon the transfer of any Stockholder Shares or Warrants (if such shares remain Stockholder Shares or Warrants as defined herein after such transfer) shall be stamped or otherwise imprinted with a legend in substantially the following form:

 “The securities represented hereby have not been registered under the Securities Act of 1933, as amended (the “Act”) and may
not be sold or transferred in the absence of an effective registration statement under the Act or an exemption from registration thereunder. The securities represented by this certificate are also subject to a Second Amended and Restated
Stockholders Agreement dated as of March 25, 2003, among the issuer of such securities (the “Company”) and certain of the Company’s equityholders, as further amended and modified from time to time in accordance with its terms. A
copy of such Stockholders Agreement will be furnished without charge by the Company to the holder hereof upon written request.” 
  

 10. 

 The Company shall imprint such legend on certificates evidencing Stockholder Shares and Warrants outstanding prior to the
date hereof. The legend set forth above shall be removed from the certificates evidencing any shares which cease to be Stockholder Shares in accordance with the definition thereof. 
 7. Sale of the Company. 
 (a) The Company may at the request of a Supermajority Vote of the Stockholders made at any time, seek to effectuate a Sale of the Company. If a Supermajority Vote of the Stockholders requests that a Sale of the Company be sought, then
(unless the Supermajority Vote directs otherwise), the Company shall promptly engage an investment banking firm of nationally-recognized standing which is selected by a Supermajority Vote of the Stockholders, to solicit bids (pursuant to a process
approved by the Board in accordance with its fiduciary duties) on behalf of the Company and the Stockholders from prospective parties to a Sale of the Company. Each of the Stockholders, the Company and the Board shall take all actions which the
Board or the Supermajority Vote of the Stockholders may reasonably request in connection with such retention and solicitation effort. Each Stockholder shall have the right to bid or participate in a bid for the Company on an arms-length basis and
the Company and the Stockholders shall consider in good faith all bona fide offers received by the Company for a Sale of the Company. 
 (b) The Company shall select from among the bids received by a Supermajority Vote of the Stockholders (and if no such Supermajority Vote is obtained shall not consummate such Sale of the Company) and shall consummate
a Sale of the Company on such terms as are approved by a Supermajority Vote of the Stockholders. If a Supermajority Vote of the Stockholders approves a Sale of the Company, whether pursuant to the procedures set forth in this Section 7 or
otherwise (an “Approved Sale”), the Company shall deliver a notice of such Approved Sale (an “Approved Sale Notice”) (which notice shall set forth the amount and form of consideration per share proposed to be paid
in connection with such Sale of the Company) to each holder of Stockholder Shares and Warrants, and each holder of Stockholder Shares and, to the extent applicable, each holder of Warrants, shall vote for, consent to and raise no objections against
such Approved Sale. In connection with an Approved Sale, each holder of Warrants hereby agrees to exercise all Warrants held by such Person no later than immediately prior to consummation of such Approved Sale (and any Warrants not so exercised
shall be deemed exercised immediately prior to consummation of such Approved Sale). If an Approved Sale is structured as a (A) merger or consolidation, each holder of Stockholder Shares (including, for such purpose, any holder of Warrants
exercising, or deemed to have exercised, such Warrants in accordance with the preceding sentence) hereby waives any dissenters’ rights, appraisal rights or similar rights in connection with such merger or consolidation or (B) sale of
stock, each holder of Stockholder Shares (including, for such purpose, any holder of Warrants exercising, or deemed to have exercised, such Warrants in accordance with the preceding sentence) hereby agrees to sell all of its Stockholder Shares
(including any Stockholder Shares received upon exercise, or deemed exercise, of Warrants pursuant to the preceding sentence) on the terms and conditions approved by the Supermajority Vote. The Company and each holder of Stockholder Shares and
Warrants shall take all necessary or desirable actions in connection with the consummation of the Approved Sale as requested by the Supermajority Vote of the Stockholders. Upon the consummation of an Approved Sale each holder of Stockholder Shares
(including for 

  

 11. 

 
such purpose all holders of Warrants exercising, or deemed to have exercised, such Warrants in connection with such Approved Sale) participating in such sale
will receive the same form of consideration and the same portion of the aggregate consideration that such Person would have received with respect to such Stockholder Shares if such aggregate consideration had been distributed by the Company in
complete liquidation pursuant to the rights and preferences set forth in the Company’s Certificate of Incorporation as in effect immediately prior to such Sale of the Company. If any holder of such Stockholder Shares (including for such purpose
all holders of Warrants, exercising, or deemed to have exercised, such Warrants in connection with such Approved Sale) fails to deliver certificates representing its Stockholder Shares or Warrants, as the case may be, as required by this
Section 7 or otherwise fails to comply with its obligations required by this Section 7, such holder (A) shall not be entitled to the consideration it is to receive in the Approved Sale until it cures such failure (provided,
that after curing such failure it shall be so entitled to such consideration without interest), (B) shall for all purposes be deemed no longer to be a stockholder of the Company and have no voting rights, (C) shall not be entitled to any
dividends or other distributions declared after the Approved Sale with respect to the Stockholder Shares held by it, (D) shall have no other rights or privileges granted to Stockholders under this or any future agreement and (E) in the
event of liquidation of the Company, its rights with respect to any consideration it would have received if it had complied with this Section 7, if any, shall be subordinate to the rights of any equity holder. Notwithstanding anything to the
contrary in this Section 7, any holder of Warrants exercising such Warrants in connection with an Approved Sale shall be entitled to rescind its exercise in the event that such Approved Sale is not consummated and to receive replacement
Warrants for the Warrants exercised in anticipation of such Approved Sale. 
 (c) The Company will pay the costs of any sale
of Stockholder Shares and Warrants pursuant to a Sale of the Company to the extent such costs are incurred for the benefit of all or substantially all of the holders of Stockholder Shares and Warrants and are not otherwise paid by the acquiring
party, but including in any event the reasonable fees and disbursements of one counsel chosen by the Nassau Group (with the approval of each of the Investor Groups, not to be unreasonably withheld). Costs incurred by any holder of Stockholder Shares
or Warrants on its own behalf will not be considered costs of the transaction hereunder. 
 (d) Each holder of Stockholder
Shares (including each holder of Warrants which exercises, or is deemed to have exercised, its Warrants in connection with such Sale of the Company) participating in a Sale of the Company shall join in and pay its share of the indemnification or
other post-closing obligations that the Company or other holders of Stockholders Shares participating in a Sale of the Company (in their capacities as such) are providing in connection with any Sale of the Company which is approved pursuant to this
Section 7 (such share being based on the excess of the amount that such holder received in connection with the consummation of such Sale of the Company over the amount that such holder would have received had the aggregate consideration from
such Sale of the Company been reduced by the aggregate amount of the indemnification and other post-closing payments that are made by the Company and the holders in connection with such Sale of the Company through the date of determination);
provided, however, that the foregoing shall not apply to any such obligations that relate specifically to a particular holder of Stockholder Shares or Warrants (such as indemnification with respect to representations and warranties given by a
holder regarding such holder’s title to and ownership of Stockholder Shares or Warrants), in which case 

  

 12. 

 
the holder to which such obligations relate shall be solely responsible therefor; provided further that no holder shall be obligated to join in and
pay its share of such indemnification or other post-closing obligations unless an Investor Group is providing, or joining in to provide, its share of such indemnification or other post-closing obligation; and provided further that no holder
shall be obligated in connection with such Sale of the Company to agree to indemnify or hold harmless the prospective transferee(s) with respect to an amount in excess of the net cash proceeds paid to such holder in connection with such Sale of the
Company. 
 (e) The restrictions set forth in this Section 7 shall terminate immediately prior to the consummation of an
IPO (as hereinafter defined). 
 8. Public Offering. If at any time a Supermajority Vote of Stockholders approves an initial Public
Offering of any equity securities of the Company to be registered under the Securities Act (an “IPO”), the holders of Stockholder Shares, the holders of Warrants and the Company will take all reasonably necessary or desirable
actions in connection with the consummation of such IPO approved by a Supermajority Vote. In the event that such IPO is an underwritten offering and the managing underwriters advise the Company in writing that in their opinion the capital stock
structure of the Company will adversely affect the marketability of the offering, each holder of Stockholder Shares and, to the extent applicable, each holder of Warrants will consent to and vote for a recapitalization, reorganization and/or
exchange of capital stock into securities that the managing underwriters and a Supermajority Vote of the Stockholders find acceptable and will take all necessary or desirable actions in connection with the consummation of the recapitalization,
reorganization and/or exchange; provided that the resulting securities reflect and are consistent with the economic values reflected by the rights and preferences set forth in the Company’s Certificate of Incorporation or Warrants (to
the extent applicable) as in effect immediately prior to the IPO. Without limiting the generality of the foregoing, if requested by the managing underwriters, each holder of Warrants will exercise such Warrants prior to such IPO, as directed by the
managing underwriters. 
 9. Preemptive Rights. 
 (a) Except for revolving or term debt obtained by the Company from financial institutions and the issuance of Common Stock, Preferred
Stock, Warrants or any other debt or equity securities of the Company (including, without limitation, any options, warrants or other securities exercisable for or convertible into shares if the Company’s equity securities) (i) to any of
the Company’s or any subsidiary’s employees, consultants, officers or directors pursuant to arrangements approved by the Board and in accordance with Section 10 below (including, without limitation, the exercise of options issued
pursuant to a stock option plan approved in accordance therewith), (ii) in connection with acquisitions approved by the Board and in accordance with Section 10 below, (iii) in connection with debt financing transactions with financial
institutions approved by the Board and in accordance with Section 10 below (including, without limitation, all Warrants and Stockholder Shares issued to New York Life Insurance Company and its transferees as contemplated by Section 27),
(iv) pursuant to a Public Offering registered under the Securities Act, or (v) pursuant to a high yield offering of debt securities pursuant to Rule 144A (or any similar or successor rule) promulgated under the Securities Act, if the
Company at any time after the date of this Agreement and prior to the consummation of the earlier of a Sale of the Company or a Qualified Public Offering, authorizes 

  

 13. 

 
the issuance or sale of any Common Stock or Preferred Stock or any securities containing options or rights to acquire any Common Stock, Preferred Stock or
any other debt or equity securities of the Company other than as a dividend on the outstanding Common Stock, the Company shall first offer to sell to each Group a portion of such stock or other securities specified in this Section 9(a). If the
stock or securities being offered are of a class of stock or securities which is outstanding prior to such issuance or are convertible into, or exercisable for, a class of stock or securities outstanding prior to such issuance, the portion of such
stock or securities offered to each Group shall be, in each case, equal to the quotient determined by dividing (1) the number of shares of stock or securities of such class (or the class into which such securities are convertible
or exercisable) held by such Group by (2) the total number of shares of stock or securities of such class (or the class into which such securities are convertible or exercisable) outstanding on a fully diluted basis immediately prior to
such issuance, and held by all Groups. If the stock or securities being offered are of a class of stock or securities which is not outstanding prior to such issuance and are not convertible into, or exercisable for, a class of stock or securities
outstanding prior to such issuance, the portion of such stock or securities offered to each Group shall, in each case, be equal to the quotient determined by dividing (1) the number of shares of Common Stock held by such Group
by (2) the total number of shares of Common Stock outstanding on a fully diluted basis immediately prior to such issuance, and held by all Groups. Each Person purchasing any stock or other debt or equity securities of the Company
pursuant to the preceding sentence shall also purchase the same percentage of any other class of Company securities (whether debt or equity) being sold with such stock or securities. Each member of each Group shall be entitled to purchase all or any
portion of such stock or securities at the most favorable price and on the most favorable terms as such stock or securities are to be offered to any other Persons. 
 (b) In order to exercise its purchase rights hereunder, each member of a Group must within 30 days after receipt of written notice from
the Company describing in reasonable detail the Common Stock, Preferred Stock or other debt or equity securities of the Company being offered, the purchase price thereof, the payment terms, the proposed closing date, and such Person’s
percentage allotment, deliver a written notice to the Company describing its election hereunder. If all of the Common Stock, Preferred Stock and other debt or equity securities of the Company offered to the members of the Groups is not fully
subscribed by such Persons, the remaining stock and securities shall be reoffered by the Company to the Groups purchasing their full allotment upon the terms set forth in this paragraph, except that such Persons must exercise their purchase rights
within 15 days after receipt of such reoffer. 
 (c) Upon the expiration of the offering periods described above, the Company
shall be entitled to sell such stock or securities which members of the Groups have not elected to purchase during the 90 days following such expiration on terms and conditions no more favorable to the purchasers thereof than those offered to such
holders. Any stock or securities offered or sold by the Company after such 90-day period must be reoffered pursuant to the terms of this Section 9. 
 (d) Notwithstanding anything contained in this Section 9 to the contrary, in connection with the issuance and sale of any Common Stock, Preferred Stock or other debt or equity securities of the Company, the
Company shall cause to be provided to the Stockholder of each Investor Group holding the largest number of Stockholder Shares such 

  

 14. 

 
information as is necessary for each such Stockholder to be satisfied in its sole discretion that, after giving effect to such issuance and sale of stock or
other securities, the transactions contemplated hereby and in the other Transaction Documents when viewed collectively, shall continue to qualify as a recapitalization for accounting purposes and each such Stockholder shall have received such
opinions and advice as it deems necessary from its accountants and advisers as to such recapitalization treatment. The Company shall not issue or sell any Common Stock, Preferred Stock or other debt or equity securities of the Company unless and
until all conditions set forth is the preceding sentence are satisfied to the satisfaction of the Stockholder of each Investor Group holding the largest number of Stockholder Shares, in its sole discretion. 
 10. Governance. Until the consummation of a Qualified Public Offering, the Company shall not take any of the following actions without the
Supermajority Vote of the Stockholders: 
 (a) directly or indirectly declare or pay any dividends or make any distributions
upon any of its capital stock or other equity securities, except for (A) dividends payable in Common Stock issued upon the outstanding Common Stock and (B) accrual or payment of dividends on Preferred Stock pursuant to the terms of the
Certificate of Incorporation; 
 (b) directly or indirectly redeem, purchase or otherwise acquire, or permit any subsidiary to
redeem, purchase or otherwise acquire, any of the Company’s or any subsidiary’s capital stock or other equity securities (including, without limitation, warrants, options and other rights to acquire such capital stock or other equity
securities) other than the Preferred Stock pursuant to the terms of the Certificate of Incorporation, except for (A) repurchases of Common Stock from employees of the Company and its subsidiaries upon termination of their employment pursuant to
arrangements approved by the Board or applicable Sub Board, (B) repurchases contemplated by this Agreement and (C) redemptions of the Warrants permitted or required by the terms set forth therein; 
 (c) except as expressly contemplated by the Stock Option Plan, the Recapitalization Agreement or the other Transaction Documents,
authorize, issue or enter into any agreement providing for the issuance (contingent or otherwise) of (A) any notes or debt securities containing equity features (including, without limitation, any notes or debt securities convertible into or
exchangeable for capital stock or other equity securities, issued in connection with the issuance of capital stock or other equity securities or containing profit participation features) or (B) any capital stock or other equity securities (or
any securities convertible into or exchangeable for any capital stock or other equity securities); provided that the Company may authorize, issue or enter into any agreement without the consent of a Supermajority Vote of the Stockholders for
the issuance of any debt or equity securities not to exceed $5,000,000 in the aggregate in any twelve-month period; 
 (d)
make, or permit any subsidiary to make, any loans or advances to, guarantees for the benefit of, or investments in, any Person (other than a wholly-owned subsidiary), except for (A) reasonable advances to employees in the ordinary course of
business, (B) acquisitions permitted pursuant to subsection (h) below and (C) investments having a stated maturity no greater than one (1) year from the date the Company makes such investment in 

  

 15. 

 
(1) obligations of the United States government or any agency thereof or obligations guaranteed by the United States government, (2) certificates of
deposit of commercial banks having combined capital and surplus of at least $50 million or (3) commercial paper with a rating of at least “Prime-I” by Moody’s Investors Service, Inc.; 
 (e) merge or consolidate with any Person or, except as permitted by subsection (h) below, permit any subsidiary to merge or
consolidate with any Person (other than the Company or another wholly-owned subsidiary of the Company), except pursuant to Section 7 hereof, 
 (f) sell, lease or otherwise dispose of, or permit any subsidiary to sell, lease or otherwise dispose of, more than 10% of the consolidated assets of the Company and its subsidiaries (computed on the basis of book
value, determined in accordance with generally accepted accounting principles consistently applied, or fair market value, determined by the Board in its reasonable good faith judgment) in any transaction or series of related transactions (other than
sales of inventory in the ordinary course of business), except pursuant to Section 7 hereof, 
 (g) liquidate, dissolve
or effect a recapitalization or reorganization in any form of transaction (including, without limitation, any reorganization into a limited liability company, a partnership or any other non-corporate entity which is treated as a partnership for
federal income tax purposes), except pursuant to Section 7 hereof, 
 (h) acquire, or permit any subsidiary to acquire,
any interest in any company or business (whether by a purchase of assets, purchase of stock, merger or otherwise), or enter into any joint venture, involving an aggregate consideration (including, without limitation, the assumption of liabilities
whether direct or indirect) exceeding $10,000,000 in any one transaction or exceeding $15,000,000 in any twelve-month period; 
 (i) enter into, or permit any subsidiary to enter into, the ownership, active management or operation of any business other than health care staffing and related businesses; 
 (j) become subject to, or permit any of its subsidiaries to become subject to (including, without limitation, by way of amendment to or
modification of), any agreement or instrument which by its terms would (under any circumstances) restrict (a) the right of any subsidiary to make loans or advances or pay dividends to, transfer property to, or repay any Indebtedness owed to,
the Company or another subsidiary or (b) the Company’s right to perform the provisions of this Agreement, the Registration Agreement, the Certificate of Incorporation or the Company’s bylaws; 
 (k) except as expressly contemplated by this Agreement in connection with issuances of Stockholder Shares permitted by this Agreement,
make any amendment to the Certificate of Incorporation (including, without limitation, increasing the authorized number of any class of capital stock of the Company) or the Company’s bylaws, or file any resolution of the board of directors with
the Delaware Secretary of State; 
  

 16. 

 (l) enter into, amend, modify or supplement, or permit any subsidiary to enter into,
amend, modify or supplement, any agreement, transaction, commitment or arrangement with any of its or any subsidiary’s officers, directors, employees, stockholders or any other Person controlling, controlled by or under common control with any
such Person or with any individual related by blood, marriage or adoption to any such individual or with any entity in which any such Person or individual owns a beneficial interest, except for customary employment arrangements with employees that
are not members of the senior management of the Company or any of its subsidiaries and benefit programs on reasonable terms and except as otherwise expressly contemplated by this Agreement; 
 (m) increase any compensation (including salary, bonuses and other forms of current and deferred compensation) payable to any officer or
director of the Company or any subsidiary, except for increases in the ordinary course of business consistent with past practice; 
 (n) establish or acquire any subsidiaries other than wholly-owned subsidiaries or any subsidiaries organized outside of the United States and its territorial possessions; 
 (o) create, incur, assume or suffer to exist, or permit any subsidiary to create, incur, assume or suffer to exist, Indebtedness exceeding
an aggregate principal amount of $5,000,000 outstanding at any time on a consolidated basis; 
 (p) create, incur, assume or
suffer to exist, or permit any subsidiary to create, incur, assume or suffer to exist, any Liens other than Permitted Liens; 
 (q) make any capital expenditures (including, without limitation, payments with respect to capitalized leases, as determined in accordance with generally accepted accounting principles consistently applied) in excess of the amounts
permitted under the Credit Agreement or any other credit documents in effect from time to time between the Company and/or its subsidiaries and their senior lenders; 
 (r) enter into any leases or other rental agreements (excluding capitalized leases, as determined in accordance with generally accepted
accounting principles consistently applied) under which the amount of the aggregate lease payments for all such agreements exceeds $1,000,000 on a consolidated basis for any twelve-month period; 
 (s) change its fiscal year; 
 (t) approve the Company’s and each subsidiary’s annual budget or incur any expenditure or take any action which would result in a material deviation from such an approved budget; 
 (u) change the authorized size of the Board from seven (7) members, except as contemplated by Section 1(c); 
 (v) amend or modify any stock option plan or employee stock ownership plan as in existence as of the Closing, adopt any new stock option
plan or employee 

  

 17. 

 
stock ownership plan or issue any Common Stock to its or its Subsidiaries employees other than pursuant to the Company’s existing stock option and
employee stock ownership plans; 
 (w) hire, terminate, suspend, promote or demote any executive employee or other member of
the Company’s senior management team or the senior management team of any of its subsidiaries; 
 (x) issue, sell or
otherwise dispose of, or permit any subsidiary to issue, sell or otherwise dispose of, any of the capital stock, or rights to acquire the capital stock, of any subsidiary to any Person other than the Company or a wholly-owned subsidiary in any
transaction or series of related transactions (other than in the ordinary course of business); or 
 (y) take any other
material action outside the Company’s ordinary course of business. 
 11. Definitions. 
 “Acacia Group” means Acacia Venture Partners (“Acacia”) and South Pointe Venture Partners together with their
respective transferees, successors and assigns that are or become a party to this Agreement (other than the Company and any Investor other than Acacia). 
 “Affiliate” of any particular Person means any other Person controlling, controlled by or under common control with such particular Person, where “control” means the possession,
directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract or otherwise. Without limiting the generality of the foregoing, an Affiliate of any Investor means
any general or limited partner of such Investor or any other individual, entity or investment fund controlling, controlled by or under common control with the Investor. 
 “Closing” shall have the meaning set forth in the Recapitalization Agreement. 
 “Frazier Group” means Frazier Healthcare IV, L.P. (“Frazier Healthcare”) and Frazier Affiliates IV, L.P. (“Frazier Affiliates”) together with their respective transferees, successors and
assigns that are or become a party to this Agreement (other than the Company and any Investor other than Frazier Healthcare or Frazier Affiliates). 
 “Group” means any Investor Group. 
 “Investor Group” means any of the Acacia Group, the Nassau
Group, the NEA Group, the Frazier Group or the Prospect Group. 
 “Nassau Group” means Nassau Capital Partners II L.P.
(“Nassau”) and NAS Partners I L.L.C. (“NAS”) together with their respective transferees, successors and assigns that are or become a party to this Agreement (other than the Company and any Investor other than Nassau
or NAS). 
 “NEA Group” means New Enterprise Associates VIII, Limited Partnership (“NEA III”), NEA
Presidents Fund, L.P. (“NEA Presidents”), NEA Ventures 1998, L.P. 

  

 18. 

 
(“NEA 1998”), New Enterprise Associates 10, Limited Partnership (“NEA 10”), New Enterprise Associates 8A, Limited
Partnership (“NEA 8A”) and Charles Linehan (“Linehan”) together with their respective transferees, successors and assigns that are or become a party to this Agreement (other than the Company and any Investor other
than NEA VIII, NEA Presidents, NEA 1998, NEA 10, NEA 8A or Linehan). 
 “Person” means an individual, a partnership, a
corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, or a governmental entity or any department, agency or political subdivision thereof. 
 “Prospect Group” means Prospect Venture Partners II, L.P. (“Prospect Venture Partners II”) and Prospect Associates II,
L.P. (“Prospect Associates II”) together with their respective transferees, successors and assigns that are or become a party to this Agreement (other than the Company and any Investor other than Prospect Venture Partners II or
Prospect Associates II). 
 “Public Offering” means the sale in a bona fide underwritten public offering registered under
the Securities Act of the Company’s equity securities approved by the Board. 
 “Public Sale” means (i) any sale
pursuant to a registered public offering under the Securities Act or (ii) any sale to the public pursuant to Rule 144 promulgated under the Securities Act effected through a broker, dealer or market maker. 
 “Qualifying Executive” means any Executive who holds Common Stock in excess of 2% of the aggregate Common Stock. 
 “Qualifying Investor Group” means any Investor Group so long as such Investor Group holds collectively at least 11% of the aggregate
Common Stock (on a fully diluted basis); provided, that each of the Frazier Group and the Prospect Group shall be a Qualifying Investor Group so long as the Frazier Group and the Prospect Group collectively hold at least 11% of the aggregate
Common Stock (on a fully diluted basis). 
 “Qualified Public Offering” means the sale in a bona fide Public Offering of the
Company’s equity securities which is approved by a Supermajority Vote of the Stockholders. 
 “Registration Rights
Agreement” means that certain Second Amended and Restated Registration Rights Agreement, dated as of the date hereof, among the Company and certain of its stockholders name therein. 
 “Sale of the Company” means (a) any sale of all or substantially all (as described in the commentary to the Model Business
Corporation Act) of the assets of the Company and its subsidiaries on a consolidated basis in one transaction or series of related transactions (but excluding sales to Affiliates), (b) any sale of greater than fifty percent (50%) of the
Common Stock in one transaction or series of related transactions or (c) a merger or consolidation, exchange of capital stock, or other transaction which accomplishes one of the foregoing. 
 “Securities Act” means the Securities Act of 1933, as amended from time to time. 
  

 19. 

 “Stockholder Shares” means (i) any Common Stock and any Preferred Stock purchased
or otherwise acquired by any Stockholder, (ii) any equity securities of the Company issued or issuable directly or indirectly with respect to the securities referred to in clause (i) above by way of stock dividend or stock split or in
connection with a combination of shares, recapitalization, merger, consolidation or other reorganization, (iii) any Common Stock and any Preferred Stock acquired by any Stockholder upon exercise of Warrants issued to or otherwise acquired by
such Stockholder, (iv) any equity securities of the Company issued or issuable directly or indirectly with respect to the securities issued upon exercise of the Warrants described in (iii) above and (v) any other class or series of
capital stock of the Company held by a Stockholder; provided that Stockholder Shares shall not include (x) any nonvoting stock for purposes of Section 1 hereof or (y) any Preferred Stock for purposes of voting or consent
hereunder (including but not limited to a Supermajority Vote hereunder). As to any particular shares constituting Stockholder Shares, such shares will cease to be Stockholder Shares when they have been (x) effectively registered under the
Securities Act and disposed of in accordance with the registration statement covering them or (y) sold to the public through a broker, dealer or market maker pursuant to Rule 144 (or any similar provision then in force) under the Securities
Act, in each case pursuant to the terms hereof. 
 “Supermajority Vote” means the affirmative vote of 66 2/3% of the
Stockholder Shares entitled to vote on the given matter. 
 “Warrants” means any warrants issued by the Company which are
exercisable into shares of Common Stock or Preferred Stock of the Company that are issued to or otherwise acquired by a Warrantholder or other Stockholder. 
 Capitalized terms used and not otherwise defined in this Agreement shall have the meanings assigned to such terms in the Recapitalization Agreement. 
 12. Transfers, Transfers in Violation of Agreement. Prior to transferring any Stockholder Shares or Warrants to any person or entity (other than
pursuant to an IPO or a Public Sale), the transferring Stockholder shall cause the prospective transferee to execute and deliver to the Company and the other Stockholders party hereto a counterpart of this Agreement and such transferee shall thereby
become a party to this Agreement as a Stockholder and an Investor, an Executive, or a Warrantholder, as applicable, hereunder. Any Transfer or attempted Transfer of any Stockholder Shares or Warrants in violation of any provision of this Agreement
shall be void, and the Company shall not record such Transfer on its books or treat any purported transferee of such Stockholder Shares or Warrants as the owner of such shares or Warrants for any purpose. 
 13. Additional Stockholders. In connection with the issuance of any additional equity securities of the Company, the Company may (with the
approval of the Board) permit such person to become, and, in the case of persons exercising stock options issued pursuant to the Stock Option Plan or any successor plan, shall upon exercise of such options require such person to become, a party to
this Agreement and to succeed to all of the rights and obligations of a “Stockholder” under this Agreement by obtaining an executed counterpart signature page to this Agreement. Upon such execution, such person shall for all purposes be a

  

 20. 

 
“Stockholder” and, as applicable, a member of a Group, an “Executive,” or a “Warrantholder” party to this Agreement.

 14. Amendment and Waiver. Except as otherwise provided herein, no modification, amendment or waiver of any provision of this
Agreement shall be effective against the Company, the Stockholders, or the Warrantholders unless such modification, amendment or waiver is approved in writing by the Company and a Supermajority Vote of the Stockholders; provided that
no such amendment or modification that would materially and adversely affect holders of one class or group of Stockholder Shares, including any Investor Group, or any group of Warrants (other than amendments and modifications in connection with the
issuances of Stockholder Shares pursuant to Section 13), shall be effective against the holders of such class or group of Stockholder Shares or Warrants without the prior written consent of: (x) Stockholders holding at least a majority of
such class or group materially and adversely affected thereby or (y) holders of Warrants exercisable into a majority of shares into which all Warrants of that materially and adversely affected group of Warrants are exercisable, as applicable;
provided further, that notwithstanding the foregoing, Section 1(a)(ii)(A)(1) of this Agreement shall not be amended or waived without the written consent of Stockholders holding a majority of the shares of Common Stock within the
Nassau Group (so long as such group is a Qualifying Investor Group); Section 1(a)(ii)(A)(2) of this Agreement shall not be amended or waived without the written consent of Stockholders holding a majority of the shares of Common Stock within the
Acacia Group (so long as such group is a Qualifying Investor Group); Section 1(a)(ii)(A)(3) of this Agreement shall not be amended or waived without the written consent of Stockholders holding a majority of the shares of Common Stock within the
Frazier Group (so long as such group is a Qualifying Investor Group); Section 1(a)(ii)(A)(4) of this Agreement shall not be amended or waived without the written consent of Stockholders holding a majority of the shares of Common Stock within the NEA
Group (so long as such group is a Qualifying Investor Group); and Section 1(a)(ii)(A)(5) of this Agreement shall not be amended or waived without the written consent of Stockholders holding a majority of the shares of Common Stock within the
NEA Group (so long as the NEA Group holds collectively at least 25% of the aggregate Common Stock (on a fully diluted basis)). The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of
such provisions and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with its terms. 
 15. Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be
invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Agreement shall be
reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. 
 16. Entire Agreement. Except as otherwise expressly set forth herein, this document embodies the complete agreement and understanding among the parties hereto with respect to the subject matter hereof and supersedes and preempts any
prior understandings, agreements or representations by or among the parties, written or oral, which may have related to the subject matter hereof in any way. 
  

 21. 

 17. Successors and Assigns. Except as otherwise provided herein, this Agreement shall bind and
inure to the benefit of and be enforceable by the Company and its successors and assigns, the Stockholders, the Warrantholders and any permitted subsequent holders of Stockholder Shares and/or Warrants and the respective successors and permitted
assigns of each of the foregoing so long as they hold Stockholder Shares and/or Warrants. 
 18. Counterparts. This Agreement may be
executed in separate counterparts each of which shall be an original and all of which taken together shall constitute one and the same agreement. 
 19. Remedies. The Company, each of the Stockholders, and the Warrantholders shall be entitled to enforce their rights under this Agreement specifically to recover damages by reason of any breach of any provision of this Agreement and
to exercise all other rights existing in their favor. The parties hereto agree and acknowledge that money damages may not be an adequate remedy for any breach of the provisions of this Agreement and that the Company, each Stockholder, and the
Warrantholders may in its sole discretion apply to any court of law or equity of competent jurisdiction for specific performance and/or injunctive relief (without posting a bond or other security) in order to enforce or prevent any violation of the
provisions of this Agreement that benefit such Person. Each of the Executives agree to not exercise any rights or remedies that such Executive may otherwise have under the Company’s Certificate of Incorporation without the Board’s consent.

 20. Notices. All notices, demands or other communications to be given or delivered under or by reason of the provisions of this
Agreement shall be in writing and shall be deemed to have been given when delivered personally to the recipient, one (1) business day after being sent to the recipient by overnight courier service (charges prepaid), upon machine-generated
acknowledgment of receipt after transmittal by facsimile or upon the date of actual receipt of being mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid. Such notices, demands and other
communications shall be sent to the Company and HEALTHSOUTH at the applicable address set forth below, to the Investors applicable addresses set forth on the Schedule of Investors, to the Executives at the applicable addresses set forth on
the Schedule of Executives, and to the Warrantholders at the applicable addresses set forth on the Schedule of Warrantholders or, in each case, to such other address or to the attention of such other person as the receipt party has
specified by prior written notice to the sending Party. 
 If to the Company: 
 CompHealth, Inc. 
 4021 South 700 East

 Salt Lake City, Utah 84107 
 Attention: Sean Dailey 
 Telephone: (801) 284-6923 
 Facsimile: (801) 284-6882 
  

 22. 

 If to HEALTHSOUTH: 
 HEALTHSOUTH Corporation 
 One HEALTHSOUTH Parkway 
 Birmingham, AL 35243 
 Attention: William W.
Horton 
 Telephone: (205) 969-4977 
 Facsimile: (205) 969-4730 
 Notwithstanding the foregoing, any notice, demand or other communication to an Investor Group shall be sent to the
attention of the Stockholder of such Investor Group which holds the largest number of Stockholder Shares. 
 21. Governing Law. The
corporate law of Delaware shall govern all issues and questions concerning the relative rights and obligations of the Company and its stockholders. All other questions concerning the construction, validity and interpretation of this Agreement shall
be governed by, and construed in accordance with, the internal laws of the State of Delaware, without giving effect to any choice of law or other conflict of law, provision or rule (whether of the State of Delaware or any other jurisdiction) that
would cause the application of the laws of any jurisdiction other than the State of Delaware. 
 22. Descriptive Headings. The
descriptive headings of this Agreement are inserted for convenience only and do not constitute a part of this Agreement. 
 23. Further
Assurances. The parties shall execute and deliver all documents, provide all information and take or refrain from taking such actions as may be necessary or appropriate to achieve the purposes of this Agreement. 
 24. No Strict Construction. The parties to this Agreement have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by such parties, and no presumption or burden of proof shall arise favoring or disfavoring any such party by virtue of the
authorship of any of the provisions of this Agreement. 
 25. Stockholder Representations. Each holder of Stockholder Shares and each
holder of Warrants hereby represents that such holder has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks or such holder’s investment in the Stockholder
Shares and/or Warrants, as applicable, and is able to bear the economic risk of such investment for an indefinite period of time. Each such holder further represents that such holder has acquired the Stockholder Shares and/or Warrants, as
applicable, for such holder’s own account and not with a view to, or intent of, distribution thereof in violation of the Securities Act, or any applicable state securities laws. 
 26. Credit Agreement Limitations. Notwithstanding anything to the contrary contained herein, the Company and each Stockholder hereby agree that no
payment of any dividends or other distributions in cash or otherwise (including pursuant to Section 7(c) of this Agreement) and no mandatory redemptions, repurchases or liquidations to the holders of Stockholder Shares shall be made by the
Company pursuant to the terms of this Agreement, the Certificate of Incorporation or otherwise, except to the extent permitted under the terms of the 

  

 23. 

 
Credit Agreement, dated as of March 23, 2000 (the “Credit Agreement”), among CompHealth, Inc., the Company, the lenders referred to
therein and Banc of America Commercial Finance Corporation, as Agent and any document that refinances or replaces the foregoing, whether in whole or in part. Nothing contained in this Section 26 shall affect any rights or impose any obligations
on the holders of Stockholder Shares or Warrants. 
 27. Stockholder Acknowledgments. 
 (a) Each Stockholder hereby acknowledges his or its consent to the Company’s and its subsidiaries’ execution, delivery and
performance of, and incurrence of their obligation under, (i) the Credit Agreement and all of the collateral documents and other agreements executed in connection therewith and (ii) the Warrant issued by the Company in favor of New York
Life Insurance Company, dated as of November 16, 2001, in each case to the extent required by Section 10 of this Agreement and hereby waives any rights of first refusal, preemptive rights and other similar rights in connection with the
issuance of the Warrants and the exercise of the Warrants into Stockholder Shares. 
 (b) Each Stockholder hereby acknowledges
his or its consent to the Company’s, HEALTHSOUTH’s, Nassau Capital Partners II L.P.’s and NAS Partners I L.L.C.’s (as applicable) execution, delivery and performance of, and incurrence of their obligations under, the Purchase
Agreements and all of the collateral documents and other agreements executed in connection therewith, in each case to the extent required by Section 10 of this Agreement, and hereby waives any rights of first refusal, preemptive rights and
other similar rights and any notice periods associated therewith, including, without limitation, any rights pursuant to Section 5 and Section 10 of the Prior Agreement, in connection with the transactions contemplated by the Purchase
Agreements. 
 28. Amendment and Restatement of Prior Agreement. The Prior Agreement is hereby amended in its entirety and restated
herein. Such amendment and restatement is effective upon the execution of the Agreement by the Company and the requisite holders pursuant to Section 15 of the Prior Agreement. Upon such execution, all provisions of, rights granted and covenants
made in the Prior Agreement are hereby waived, released and superseded in their entirety and shall have no further force or effect, including, without limitation, all rights under Section 5 and Section 10 of the Prior Agreement, rights of
first refusal and co-sale and any notice periods associated therewith otherwise applicable to the transactions contemplated by the Purchase Agreements. HEALTHSOUTH hereby acknowledges that upon the effectiveness of this Agreement, HEALTHSOUTH shall
have no further rights pursuant to the Prior Agreement and any and all such rights shall have no further force or effect. 
 * * * * *

  

 24. 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amended and Restated Stockholders
Agreement on the day and year first above written. 
  

			
	 COMPHEALTH GROUP, INC.

		
	 By:
	 	

	 Its:
	 	 CFO

	
	 HEALTHSOUTH CORPORATION

		
	 By:
	 	  
	 Its:
	 	  

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amended and Restated Stockholders
Agreement on the day and year first above written. 
  

			
	 COMPHEALTH GROUP, INC.

		
	 By:
	 	  
	 Its:
	 	  
	
	 HEALTHSOUTH CORPORATION

		
	 By:
	 	

	 Its:
	 	 EVP

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

			
	 NASSAU CAPITAL PARTNERS II L.P.
 By: Nassau Capital L.L.C., its general partner

		
	 By:
	 	

	 Its:
	 	  
	
	 NAS PARTNERS I L.L.C.

		
	 By:
	 	

	 Its:
	 	  

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

			
	 Acacia Venture Partners, L.P.

	 By: Acacia Management, L.P., It’s General Partner

		
	 By:
	 	

		 	 C. Sage Givens, General Partner

	
	 South Pointe Venture Partners, L.P.

		
	 By:
	 	

		 	 C. Sage Givens, General Partner

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

			
	 NEW ENTERPRISE ASSOCIATES VIII,

	 LIMITED PARTNERSHIP

		
	 By:
	 	 NEA Partners VIII, Limited Partnership

	 Its:
	 	 General Partner

		
	 By:
	 	

	 Its:
	 	 General Partner

	
	 NEA PRESIDENTS FUND, L.P.

		
	 By:
	 	 NEA Presidents Partners, L.P.

	 Its:
	 	 General Partner

		
	 By:
	 	

	 Its:
	 	 General Partner

	
	 NEA VENTURES 1998, L.P.

		
		 	

	 By:
	 	 Nancy Dorman

	 Its:
	 	 Vice President

	
	NEW ENTERPRISE ASSOCIATES 10,
	LIMITED PARTNERSHIP
	By:	 	 NEA Partners 10, Limited Partnership
 its General Partner

		
	 By:
	 	

		 	 General Partner

			
	 NEW ENTERPRISE ASSOCIATES 8A,

	 LIMITED PARTNERSHIP

	BY:	 	 NEA Partners 10, Limited Partnership
 its General Partner

		
	BY:	 	

		 	 General Partner

	
	  
	 Charles Linehan

			
	 NEW ENTERPRISE ASSOCIATES 8A,

	 LIMITED PARTNERSHIP

	BY:	 	 NEA Partners 10, Limited Partnership
 its General Partner

		
	BY:	 	  
		 	 General Partner

	
	

	 Charles Linehan

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

	
	
	

	 Michael Weinholtz

	
	  
	 Sean Dailey

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

	
	
	  
	 Michael Weinholtz

	
	

	 Sean Dailey

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

			
	Frazier Healthcare IV, L.P.
	 By
	 	FHM IV, LP, its general partner
	 By
	 	FHM IV, LLC, its general partner
		
	By	 	

		 	 Nader Naini, Member

  

			
	Frazier Affiliates IV, L.P.
	 By
	 	FHM IV, LP, its general partner
	 By
	 	FHM IV, LLC, its general partner
		
	By	 	  
		 	 Nader Naini, Member

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

			
	Frazier Healthcare IV, L.P.
	 By
	 	FHM IV, LP, its general partner
	 By
	 	FHM IV, LLC, its general partner
		
	By	 	  
		 	 Nader Naini, Member

  

			
	Frazier Affiliates IV, L.P.
	 By
	 	FHM IV, LP, its general partner
	 By
	 	FHM IV, LLC, its general partner
		
	By	 	

		 	 Nader Naini, Member

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

			
	PROSPECT VENTURE PARTNERS II, L.P.
		
	By:	 	 Prospect Management Co. II, LLC

		 	 its General Partner

		
	By:	 	

		 	 James Tananbaum

		 	 Managing Member

	
	PROSPECT ASSOCIATES II, L.P.
		
	By:	 	 Prospect Management Co. II, LLC

		 	 its General Partner

		
	By:	 	

		 	 James Tananbaum

		 	 Managing Member

 [SIGNATURE PAGE TO SECOND AMENDED AND RESTATED 
 STOCKHOLDERS AGREEMENT] 
  

							
	 NEW YORK LIFE INSURANCE

	 COMPANY

		
	 By:
	 	

		 	 Name:
	 	 Anthony R. Malloy

		 	 Title:
	 	 Investment Vice President

 SCHEDULE OF INVESTORS 
 Nassau Capital Partners II L.P. 
 NAS Partners I L.L.C. 
 Acacia Venture Partners, L.P. 
 South Pointe
Venture Partners, L.P. 
 New Enterprise Associates, Limited Partnership 
 New Enterprise Associates VIII, Limited Partnership 
 NEA Ventures 1998, L.P.

 NEA Presidents Fund, L.P. 
 New
Enterprise Associates 10, Limited Partnership 
 New Enterprise Associates 8A, Limited Partnership 
 Charles Linehan 
 Frazier Healthcare IV, L.P.

 Frazier Affiliates IV, L.P. 
 Prospect Venture Partners II, L.P. 
 Prospect Associates II, L.P. 

 SCHEDULE OF EXECUTIVES 
 Michael Weinholtz 
 Sean Dailey 

 SCHEDULE OF WARRANTHOLDERS 
 New York Life Insurance Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]